{"gene":"HMMR","run_date":"2026-06-10T01:55:22","timeline":{"discoveries":[{"year":1994,"finding":"RHAMM contains two HA-binding domains near the C-terminus defined by a B(X7)B motif (two basic amino acids flanking a seven-amino-acid stretch). Site-directed mutagenesis of K423, R431, and adjacent basic residues abolished HA binding; mutation of all B(X7)B motifs in recombinant RHAMM eliminated HA binding entirely. The same motif, when grafted onto the non-binding N-terminus of RHAMM, conferred HA binding, confirming this motif is necessary and sufficient for HA binding in RHAMM, CD44, and link protein.","method":"Site-directed mutagenesis of recombinant RHAMM fusion proteins, HA-Sepharose binding assays, chimeric protein construction, transblot analysis","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution with recombinant proteins, mutagenesis of specific residues, chimeric rescue experiments, replicated across multiple constructs in one rigorous study","pmids":["7508860"],"is_preprint":false},{"year":1994,"finding":"RHAMM also contains a heparin-binding domain co-localizing with the HA-binding B(X7)B region at the C-terminus. Heparin at physiological concentrations (0.1 mg/ml) stimulated cell locomotion in a RHAMM-dependent manner (blocked by anti-RHAMM antibodies), while low concentrations (0.01 mg/ml) inhibited HA-induced locomotion independently of RHAMM. GST-RHAMM fusion protein bound biotin-labeled heparin in ligand blotting assays; deletion of HA-binding domains abolished heparin binding.","method":"Ligand blotting, HA-Sepharose/HP-Sepharose affinity chromatography, deletion analysis of fusion proteins, antibody neutralization of cell locomotion","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — in vitro binding assays with recombinant proteins and deletion mutants, functional locomotion assays; single lab","pmids":["7534313"],"is_preprint":false},{"year":1994,"finding":"HA stimulation of ras-transformed fibroblast motility via RHAMM promotes rapid, transient protein tyrosine phosphorylation (within 1 min, dissipating by 10–15 min) and focal adhesion kinase (pp125FAK) phosphorylation/dephosphorylation, accompanied by rapid assembly and disassembly of focal adhesions (monitored by vinculin immunofluorescence). Tyrosine kinase inhibitors and microinjected anti-phosphotyrosine antibodies blocked both the phosphorylation and HA-stimulated motility. Anti-RHAMM antibodies reproduced the same tyrosine phosphorylation and focal adhesion turnover as HA.","method":"Immunoblot with anti-phosphotyrosine antibodies, immunofluorescence of vinculin, microinjection of antibodies, tyrosine kinase inhibitors (genistein, herbimycin A), time-course kinase assay","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (immunoblot, immunofluorescence, microinjection, pharmacological inhibition), consistent results across approaches, foundational mechanism paper","pmids":["7518470"],"is_preprint":false},{"year":1993,"finding":"TGF-β1 stimulates cell locomotion by inducing transcription, synthesis, and membrane expression of RHAMM and coincident HA secretion. Anti-RHAMM antibodies and RHAMM HA-binding domain peptides suppressed TGF-β1-induced motility, placing RHAMM downstream of TGF-β1 in the motility pathway.","method":"Antibody neutralization, antisense oligonucleotides, exogenous TGF-β1 treatment, anti-RHAMM peptides, TGF-β1-transfected cell models","journal":"The Journal of cell biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional epistasis via multiple inhibitory approaches; single lab","pmids":["7693717"],"is_preprint":false},{"year":1993,"finding":"On ras-transformed fibroblasts, RHAMM (not CD44) is the primary mediator of HA-promoted cell locomotion. Anti-RHAMM antibodies completely inhibited HA-stimulated locomotion, whereas multiple anti-CD44 antibodies that block HA/CD44 interactions had no effect on locomotory responses to HA.","method":"Antibody neutralization assays, transblot HA-binding assay comparing CD44 and RHAMM, time-lapse locomotion assays","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional antibody neutralization with multiple anti-CD44 clones as controls; single lab","pmids":["7688314"],"is_preprint":false},{"year":1995,"finding":"Overexpression of RHAMM transforms fibroblasts and causes spontaneous lung metastases. A dominant-suppressor RHAMM mutant reverses H-ras transformation and tumorigenicity; antisense reduction of RHAMM renders fibroblasts resistant to ras transformation. RHAMM acts downstream of ras, and loss of functional RHAMM ablates focal adhesion kinase (FAK) phosphorylation changes and prevents focal adhesion turnover in response to HA.","method":"Transfection overexpression, dominant-negative suppressor mutant, antisense transfection, in vivo tumor/metastasis assay, focal adhesion kinase phosphorylation analysis","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (dominant-negative + antisense + overexpression), in vivo tumor models, FAK phosphorylation readout; landmark study with multiple orthogonal approaches","pmids":["7541721"],"is_preprint":false},{"year":1996,"finding":"Soluble RHAMM induces G2/M cell cycle arrest by suppressing Cdc2/Cyclin B1 expression through increased cdc2 mRNA degradation. Dominant-negative RHAMM mutants and antisense mRNA knockdown also decreased Cdc2 protein levels, linking RHAMM to mitotic entry control.","method":"Soluble RHAMM protein treatment, dominant-negative mutants, antisense knockdown, Western blot for Cdc2/Cyclin B1, mRNA stability assay, in vivo metastasis assay","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple genetic approaches to perturb RHAMM, mRNA degradation assay; single lab","pmids":["8666924"],"is_preprint":false},{"year":1998,"finding":"RHAMM isoforms differ in subcellular localization: isoforms encoding exon 4 occur on the cell surface and in the cytoplasm; RHAMMv4 (encoding exon 4) is exclusively cytoplasmic. Intracellular RHAMMv4 regulates ERK1/2 activity: anti-RHAMM exon 4 antibodies block PDGF-induced ERK activation; a dominant-negative RHAMMv4 inhibits mutant active Ras-stimulated ERK activation and co-immunoprecipitates with MEK1 and ERK, indicating RHAMMv4 acts as an adaptor at the MEK–ERK level. Overexpression of RHAMMv4 constitutively activates ERK.","method":"Flow cytometry, confocal microscopy, epitope-tagging, co-immunoprecipitation with MEK1/ERK, dominant-negative expression, ERK kinase assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — co-IP of MEK1/ERK complex, dominant-negative epistasis, constitutive activation overexpression, localization by flow cytometry and confocal; multiple orthogonal methods in one study","pmids":["9556628"],"is_preprint":false},{"year":1999,"finding":"Intracellular RHAMM/IHABP co-localizes with microtubules in interphase and dividing cells and is a novel microtubule-associated protein (MAP). Microtubule-binding region was mapped to the extreme N-terminus using deletion mutants fused to GFP; two subdomains are required for interphase microtubule binding, while one subdomain is sufficient for mitotic spindle binding. RHAMM/IHABP also interacts with actin filaments in vivo and in vitro. A calmodulin-binding site within residues 574–602 mediates Ca2+-dependent calmodulin binding.","method":"GFP fusion protein expression, microtubule co-sedimentation/binding assays, deletion mutant transfection, in vitro actin co-sedimentation, calmodulin-affinity chromatography","journal":"Journal of cell science","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — in vitro binding assays with deletion mutants, GFP co-localization, calmodulin affinity chromatography; multiple orthogonal methods in one study","pmids":["10547355"],"is_preprint":false},{"year":2003,"finding":"RHAMM localizes to centrosomes and is required for spindle pole stability. The N-terminus binds microtubules, while a separate C-terminal domain (72% identical to the dynein-interaction domain of Xklp2) is required for centrosomal targeting. Anti-RHAMM antibodies co-immunoprecipitate dynein intermediate chain (dynein IC) from Xenopus and HeLa extracts. Deregulation of RHAMM expression inhibits mitotic progression and disrupts spindle architecture.","method":"Immunofluorescence, co-immunoprecipitation of dynein IC, deletion mutant analysis, overexpression/knockdown cell biology, phylogenetic analysis","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP with dynein, domain mapping with deletion mutants, centrosomal localization confirmed by immunofluorescence, functional deregulation phenotype; multiple methods in one study","pmids":["12808028"],"is_preprint":false},{"year":2006,"finding":"Cell surface Rhamm is required for localization of CD44 to the cell surface, formation of CD44–ERK1,2 complexes, and nuclear targeting of activated ERK1,2 in fibroblasts. Rhamm−/− fibroblasts fail to resurface scratch wounds or invade HA-supplemented collagen gels; these defects are rescued by cell-surface-restricted recombinant Rhamm (bead-linked) or by expression of constitutively active MEK1, establishing that Rhamm acts upstream of ERK1,2 in this motogenic pathway. ERK1,2 activation and fibroblast migration/differentiation are also defective during skin wound repair in vivo in Rhamm−/− mice.","method":"Rhamm−/− genetic knockout mice, scratch wound assay, collagen gel invasion, co-immunoprecipitation (CD44–ERK1,2), subcellular fractionation, bead-linked recombinant Rhamm rescue, mutant active MEK1 rescue, in vivo excisional wound model","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with in vitro and in vivo phenotypes, reciprocal co-IP, mechanistic rescue experiments with both recombinant protein and active MEK1; multiple orthogonal methods","pmids":["17158951"],"is_preprint":false},{"year":2007,"finding":"Cell surface Rhamm and CD44 form a complex with ERK1,2 that sustains high basal ERK1,2 activity and motility in invasive breast cancer cells, dependent on endogenous hyaluronan synthesis. CD44, Rhamm, and ERK1,2 uniquely co-immunoprecipitate and co-localize in invasive MDA-MB-231 and Ras-MCF10A cells but not in less invasive lines. Combined anti-CD44 + anti-Rhamm antibodies and MEK1 inhibitor showed less-than-additive effects, indicating action on a common pathway.","method":"Co-immunoprecipitation, co-localization by immunofluorescence, antibody neutralization, MEK1 inhibitor (PD098059), siRNA knockdown of HA synthase","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal co-IP, co-localization, pharmacological epistasis, HA synthesis inhibition; multiple orthogonal methods in one study","pmids":["17392272"],"is_preprint":false},{"year":2007,"finding":"RHAMM physically associates with the receptor tyrosine kinase RON (recepteur d'origine nantais) at the apex of ciliated airway epithelial cells. Oxidative degradation of apical HA produces low-molecular-weight HA fragments that signal via RHAMM and RON to increase ciliary beat frequency (CBF). A function-blocking anti-RHAMM antibody reduced the CBF response; co-immunoprecipitation confirmed physical RHAMM–RON association.","method":"Co-immunoprecipitation, immunohistochemistry, function-blocking antibodies, tyrosine kinase inhibitor (genistein), RON inhibitor (β-MSP), HA synthesis inhibition","journal":"American journal of respiratory cell and molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP confirming physical interaction, functional antibody blocking, pharmacological inhibitors; single lab","pmids":["17395888"],"is_preprint":false},{"year":2006,"finding":"RHAMM, not CD44, mediates HA-induced vascular smooth muscle cell migration through a PI3K-dependent Rac activation pathway. siRNA knockdown of RHAMM inhibited both HA-induced migration and Rac activation; siRNA knockdown of CD44 inhibited RhoA activation without affecting migration. PI3K inhibitor LY294002 blocked HA-induced Rac activation and migration downstream of RHAMM.","method":"siRNA knockdown of RHAMM and CD44, Rho GTPase pull-down activity assays, PI3K inhibitor, Rho kinase inhibitor, blocking anti-CD44 antibody, migration assays","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA epistasis with pull-down assays for Rac/RhoA activity, pharmacological dissection; single lab","pmids":["16934786"],"is_preprint":false},{"year":2008,"finding":"Intracellular RHAMM associates with BRCA1 and BARD1; this association attenuates the mitotic-spindle-promoting activity of RHAMM. Extracellular RHAMM–CD44 partnering sustains CD44 surface display and enhances CD44-mediated ERK1/2 signaling.","method":"Co-immunoprecipitation (RHAMM–BRCA1, RHAMM–BARD1, RHAMM–CD44), cell surface display assays, ERK1/2 signaling assays (as described in cited primary studies reviewed here)","journal":"Journal of cell science","confidence":"Low","confidence_rationale":"Tier 3 / Weak — review paper summarizing co-IP data from primary studies; mechanistic claims are based on previously published work, not new experiments in this paper","pmids":["18354082"],"is_preprint":false},{"year":2010,"finding":"Intracellular RHAMM(Δ163) regulates interphase and mitotic spindle microtubule stability through ERK1,2 activity. RHAMM−/− MEFs show strongly acetylated interphase microtubules, multipolar spindles, and aberrant cytokinesis, rescued by RHAMM or mutant active MEK1. RHAMM(Δ163) binds α- and β-tubulin via a C-terminal leucine zipper and directly binds ERK1 via a D-site motif (confirmed by co-IP and pulldown). RHAMM(Δ163)–ERK1/2–MEK1–tubulin complexes identified; RHAMM mutants defective in ERK1 binding fail to rescue microtubule defects.","method":"RHAMM−/− MEFs, mutant active MEK1 rescue, co-immunoprecipitation/pulldown of RHAMM–ERK1/2–MEK1–tubulin, in vitro tubulin polymerization assay, D-site mutant analysis, in vitro kinase assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — genetic KO rescue, in vitro binding assays, mutagenesis of ERK1-binding D-site, in vitro kinase assays; multiple orthogonal methods in one rigorous study","pmids":["20558733"],"is_preprint":false},{"year":2011,"finding":"BRCA1 and RHAMM, together with AURKA and TPX2, cooperate in essential microtubule reorganization during MCF10A apicobasal polarization. BRCA1 facilitates this reorganization, while AURKA impairs it; RHAMM and TPX2 form a negative feedback loop regulating AURKA. Mechanistically, elevated RHAMM and TPX2 oppose AURKA activity at the mitotic cell cortex during polarization.","method":"MCF10A 3D polarization assay, siRNA knockdown of BRCA1/RHAMM/AURKA/TPX2, immunofluorescence, genetic association analysis in BRCA1 mutation carriers","journal":"PLoS biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — 3D cell polarization functional assay with siRNA epistasis and imaging; single lab, but multiple orthogonal methods","pmids":["22110403"],"is_preprint":false},{"year":2013,"finding":"RHAMM expression is transcriptionally controlled by YAP/TEAD: YAP binds RHAMM promoter at specific sites and drives RHAMM transcription. Mevalonate pathway activity regulates YAP phosphorylation and nuclear-cytoplasmic localization, thereby controlling RHAMM transcription. Simvastatin inhibits breast cancer cell migration/invasion by reducing YAP-activated RHAMM transcription via geranylgeranylation, Rho GTPase activation, and actin cytoskeleton rearrangement, largely independently of MST/LATS kinase activity.","method":"Reporter assays (RHAMM promoter luciferase), ChIP for YAP/TEAD binding, siRNA knockdown of YAP, simvastatin treatment, geranylgeraniol rescue, YAP phosphorylation and localization analysis, in vitro/in vivo migration/invasion assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP demonstrating direct YAP/TEAD-promoter binding, reporter assays, siRNA epistasis, pharmacological rescue, in vivo validation; multiple orthogonal methods","pmids":["24367099"],"is_preprint":false},{"year":2014,"finding":"RHAMM is required for Aurora kinase A activation and correct TPX2 localization during mitotic spindle assembly. Silencing RHAMM delays spindle assembly kinetics, mislocalizes TPX2, and attenuates localized Aurora kinase A activation, reducing mitotic spindle length. The RHAMM–TPX2 complex requires a C-terminal basic leucine zipper in RHAMM and a domain including the nuclear localization signal in TPX2.","method":"siRNA silencing, live-cell imaging of spindle assembly kinetics, immunofluorescence of Aurora kinase A activity (pAURKA), co-immunoprecipitation of RHAMM–TPX2, deletion mutant analysis","journal":"Cell cycle","confidence":"High","confidence_rationale":"Tier 2 / Strong — co-IP with domain mapping, live-cell kinetics, phospho-AURKA immunofluorescence, siRNA phenotype; multiple orthogonal methods in one study","pmids":["24875404"],"is_preprint":false},{"year":2014,"finding":"RHAMM acts as a co-activator of E2F1 to transcriptionally up-regulate fibronectin. E2F1 directly up-regulates RHAMM, which in turn enhances E2F1-mediated fibronectin expression and integrin-β1–FAK signaling, promoting cytoskeletal remodeling and tumor cell transmigration across endothelial layers. RHAMM depletion abolishes fibronectin expression and endothelial transmigration in E2F1-activated cells.","method":"Co-immunoprecipitation (E2F1–RHAMM), ChIP for E2F1 binding to RHAMM promoter, siRNA knockdown, fibronectin promoter reporter assay, transmigration assays, xenograft in vivo model","journal":"The Journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, ChIP, reporter assay, functional transmigration assay; single lab","pmids":["25042645"],"is_preprint":false},{"year":2015,"finding":"In zebrafish heart regeneration, HA and Hmmr are required for epicardial epithelial-to-mesenchymal transition (EMT) and epicardial cell migration into the regenerating ventricle. Chemical inhibition of FAK or Src kinases (downstream effectors of Hmmr) prevented epicardial cell migration, implicating a HA/Hmmr/FAK/Src pathway in cardiac regeneration.","method":"Zebrafish morpholino knockdown of Hmmr, HA synthesis inhibitor, chemical inhibition of FAK and Src, ventricular resection model, proteomics identification of Hmmr","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockdown with FAK/Src pharmacological epistasis in zebrafish; single lab, ortholog study","pmids":["26156497"],"is_preprint":false},{"year":2016,"finding":"RHAMM regulates planar germ cell division in the testis by associating with the mitotic spindle; loss of RHAMM from the spindle causes defective planar divisions of undifferentiated germ cells, leading to premature niche exit, germ cell depletion, hypofertility, and seminoma. RHAMM expression in testis is regulated by the testis-specific polyadenylation protein CFIm25, which is downregulated in human seminomas.","method":"Mouse models (Rhamm knockout, CFIm25 models), immunofluorescence of spindle-associated RHAMM, analysis of human seminoma specimens, CFIm25 expression studies","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO mouse model with defined spindle orientation phenotype, human seminoma validation; single lab","pmids":["27543603"],"is_preprint":false},{"year":2017,"finding":"HMMR acts at centrosomes in a PLK1-dependent pathway that localizes active Ran and modulates cortical NuMA–dynein complex positioning to correct mispositioned mitotic spindles. Hmmr-knockout mice exhibit neonatal lethality with defective neural development and spindle orientation defects. HMMR overexpression induces phenotypes consistent with increased active Ran including spindle orientation defects.","method":"Hmmr-knockout mouse generation and phenotyping, immunofluorescence (active Ran, NuMA, dynein at cortex), PLK1 pathway epistasis, spindle orientation quantification in neural progenitors","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with in vivo developmental phenotype, mechanistic pathway placement via Ran/NuMA/dynein localization, PLK1 epistasis, overexpression phenotype; multiple orthogonal methods","pmids":["28994651"],"is_preprint":false},{"year":2018,"finding":"HMMR acts as a nonmotor adaptor that dampens Eg5-mediated forces during mitosis by localizing TPX2 and promoting formation of inhibitory TPX2–Eg5 complexes. Genomic deletion or siRNA silencing of HMMR disturbs spindle microtubule organization, bipolar kinetochore attachments, and increases aneuploidy. A conserved HMMR motif with homology to kinesin Kif15 is required for interkinetochore tension and anaphase entry. HMMR defects are alleviated by chemical inhibition of Eg5 but not Kif15 silencing.","method":"siRNA silencing, HMMR genomic deletion, live-cell imaging, immunofluorescence (kinetochore tension, spindle architecture), chemical inhibition of Eg5 and Kif15 silencing, aneuploidy quantification, rescue with conserved motif constructs","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic deletion and siRNA with mechanistic rescue, multiple spindle/kinetochore functional readouts, Eg5 inhibitor epistasis; multiple orthogonal methods in one study","pmids":["29386294"],"is_preprint":false},{"year":2018,"finding":"Phosphorylation of BACH1 during mitosis is required for its interaction with HMMR and CRM1 to stabilize mitotic spindle orientation. Mitosis-specific phosphorylations of BACH1 were identified by SILAC mass spectrometry; mutation of these phosphorylation sites abolished both spindle orientation rescue and HMMR interaction in BACH1-depleted cells. BACH1 loses chromatin/gene expression partners during mitosis but retains interaction with HMMR.","method":"SILAC mass spectrometry, co-immunoprecipitation (BACH1–HMMR), phosphomutant expression rescue, spindle orientation imaging, BACH1 knockdown and re-expression","journal":"The Biochemical journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — SILAC MS identification of phosphorylation, co-IP, phosphomutant rescue; single lab","pmids":["29459360"],"is_preprint":false},{"year":2008,"finding":"RHAMM expression is transcriptionally downregulated by p53. Reporter assays showed p53-dependent repression is mediated at the RHAMM promoter (including first exon and first intron). RHAMM protein levels peak in S phase and decrease before the G2/M mRNA peak, indicating post-transcriptional control in addition to transcriptional regulation during the cell cycle.","method":"Reporter assays (RHAMM promoter luciferase), p53-inducible transgenic cell system, nutlin-3/doxorubicin/paclitaxel treatment, RT-PCR and Western blot across cell cycle fractions","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter assays, p53-inducible system, multiple p53-activating agents; single lab","pmids":["18971636"],"is_preprint":false},{"year":2001,"finding":"In rat brain, RHAMM exists as multiple molecular weight forms (66, 75, 85–90 kDa) with differential subcellular distribution. The 75 kDa form is enriched in mitochondrial fractions and associates with mitochondrial membranes (retained in osmotically shocked mitochondria, liberated by alkali carbonate). Brain RHAMM binds calmodulin in a Ca2+-dependent manner via calmodulin-affinity chromatography.","method":"Subcellular fractionation, Western blotting, osmotic shock/alkali carbonate extraction of mitochondria, calmodulin-affinity chromatography, HA-Sepharose chromatography, double immunohistochemistry with cytochrome oxidase","journal":"Journal of neuroscience research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — subcellular fractionation with biochemical extraction controls, calmodulin affinity chromatography, immunohistochemical co-localization; single lab","pmids":["11433424"],"is_preprint":false},{"year":2022,"finding":"HMMR overexpression in mouse mammary epithelium increases Brca1-mutant tumorigenesis by activating AURKA, reducing ARPC2 localization at the mitotic cell cortex, promoting micronucleation, and activating cGAS-STING and non-canonical NF-κB signaling. Initial tumorigenic events include genomic instability, epithelial-to-mesenchymal transition, and tissue infiltration of tumor-associated macrophages.","method":"Transgenic mouse mammary epithelium overexpression of HMMR crossed with Brca1 mutant, immunofluorescence (AURKA, ARPC2 cortical localization), micronucleus assay, cGAS-STING pathway activation assays, NF-κB reporter/assays, macrophage infiltration histology","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo transgenic mouse model with mechanistic pathway readouts; single lab, multiple downstream phenotypic measurements","pmids":["35393420"],"is_preprint":false},{"year":2013,"finding":"RHAMM interacts with ANKRD26 as identified by yeast two-hybrid and co-immunoprecipitation. Selective down-regulation of Hmmr in 3T3-L1 cells increased adipogenesis, indicating RHAMM suppresses this differentiation process.","method":"Yeast two-hybrid, co-immunoprecipitation, siRNA knockdown, adipogenesis assay (Oil Red O)","journal":"PloS one","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single co-IP confirmation of yeast two-hybrid interaction; adipogenesis phenotype from single siRNA experiment; single lab","pmids":["22666460"],"is_preprint":false},{"year":2016,"finding":"RHAMM forms an intracellular complex with β-catenin that protects β-catenin from degradation and supports its nuclear translocation, resulting in c-Myc activation and enhanced fibrosarcoma cell proliferation. LMWHA increases HT1080 cell growth in a RHAMM-dependent manner through this β-catenin/c-Myc axis.","method":"Co-immunoprecipitation (RHAMM–β-catenin), immunofluorescence, siRNA knockdown, transfection experiments with c-Myc reporter, cell proliferation assays","journal":"Biochimica et biophysica acta","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP of RHAMM–β-catenin complex, siRNA epistasis, reporter assays; single lab","pmids":["26825774"],"is_preprint":false},{"year":2020,"finding":"RHAMM-dependent RHAMM/CD44 complexation is upregulated specifically by immobilized (end-on) HA but not by soluble HA in breast cancer cells. CD44/RHAMM co-localization and complexation were demonstrated by FRET microscopy and co-immunoprecipitation; this interaction is regulated in a cell-specific feedback loop via HA presentation format.","method":"FRET microscopy, co-immunoprecipitation, immunocytochemistry, comparison of soluble vs. immobilized HA substrates","journal":"Acta biomaterialia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — FRET and co-IP are complementary orthogonal methods; single lab, findings on HA presentation dependency","pmids":["33091625"],"is_preprint":false},{"year":2023,"finding":"HMMR promotes prostate cancer progression through a positive feedback loop: HMMR interacts with AURKA and stabilizes AURKA protein by inhibiting its ubiquitination-mediated degradation, which activates mTORC2/AKT signaling; activated AKT promotes E2F1-driven transcription of HMMR, forming a reinforcing loop. mTOR inhibitor partially antagonized HMMR-mediated tumor growth in vivo.","method":"Co-immunoprecipitation (HMMR–AURKA), ubiquitination assay, mTORC2/AKT phosphorylation analysis, E2F1 ChIP on HMMR promoter, gain/loss-of-function in vitro/in vivo, mTOR inhibitor treatment","journal":"Cell death discovery","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, ubiquitination assay, ChIP, in vivo rescue; single lab","pmids":["36750558"],"is_preprint":false},{"year":2023,"finding":"HMMR forms a complex with FAK and SRC in the cytoplasm to activate NF-κB signaling, independently of membrane CD44 interaction, thereby sustaining CD47 ('don't eat me') signaling and enabling liver cancer immune evasion. HMMR knockout inhibited liver cancer growth and enhanced phagocytosis by macrophages; targeting HMMR enhanced anti-PD-1 treatment by recruiting CD8+ T cells.","method":"HMMR−/− liver cancer mouse model, co-immunoprecipitation (HMMR–FAK–SRC), NF-κB reporter assay, CD47 expression analysis, phagocytosis assays, anti-PD-1 combination in vivo","journal":"Science advances","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO, co-IP of cytoplasmic complex, NF-κB pathway readout, phagocytosis functional assay; single lab","pmids":["38838151"],"is_preprint":false},{"year":2020,"finding":"In HCC progression driven by ER stress, HMMR is transcriptionally induced by the ER stress transcription factor CHOP and is ubiquitinated and degraded by the E3 ligase TRIM29. Dynamic TRIM29 expression during HCC progression regulates dynamic HMMR protein expression. HMMR alleviates ER stress by promoting autophagic lysosome activity.","method":"Co-immunoprecipitation, ubiquitination assay (TRIM29–HMMR), luciferase reporter assay (CHOP binding to HMMR promoter), ChIP, immunofluorescence (HMMR–autophagy markers), HBV-transgenic mouse model","journal":"Cancer communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP, ubiquitination assay, ChIP/luciferase for transcriptional regulation, in vivo mouse model; single lab, multiple orthogonal methods","pmids":["37405956"],"is_preprint":false},{"year":2019,"finding":"RHAMMB isoform (lacking the 15 aa encoded by alternative exon present in RHAMMA) but not RHAMMA promotes pancreatic tumor metastasis in vivo. RHAMMB upregulation in liver metastases correlates with higher EGFR expression, and EGFR knockdown abolished RHAMMB-driven metastasis, placing RHAMMB upstream of EGFR-dependent signaling.","method":"RNA-Seq isoform analysis of primary PNET and liver metastases, experimental metastasis mouse models, EGFR knockdown (siRNA), in vivo spontaneous metastasis assays","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — isoform-specific in vivo metastasis models, EGFR epistasis via siRNA; single lab","pmids":["31072393"],"is_preprint":false},{"year":2013,"finding":"RHAMM cytoplasmic localization is required for maintenance of murine embryonic stem cell pluripotency via modulation of ERK1/2 and Aurora kinase A activity at microtubules. RHAMM was not detectable on the ESC cell surface. Hemizygous genomic deletion of Hmmr augmented differentiation and attenuated pluripotency; inhibition of ERK1/2 or Aurora kinase A rescued pluripotency in RHAMM+/− ESCs.","method":"Hemizygous Hmmr genomic deletion, immunofluorescence localization in ESCs, small-molecule kinase inhibitor screen, differentiation/pluripotency marker analysis","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic hemizygous deletion with functional pluripotency phenotype, kinase inhibitor epistasis, localization studies; single lab","pmids":["24019927"],"is_preprint":false}],"current_model":"HMMR/RHAMM is a multifunctional, multispatial protein that (1) binds hyaluronan extracellularly via a defined B(X7)B motif and signals through a RHAMM–CD44–ERK1/2 complex to promote cell motility and wound repair, acting downstream of Ras and TGF-β; (2) localizes intracellularly to microtubules, centrosomes, and mitotic spindles, where it stabilizes spindle integrity by cross-linking microtubules via dynein co-association, localizing TPX2 and active Aurora kinase A, dampening Eg5-mediated forces via TPX2–Eg5 complexes, and acting in a PLK1-dependent pathway to orient spindle position through regulation of active Ran and cortical NuMA–dynein; and (3) functions as a signaling adaptor that recruits ERK1/2–MEK1 complexes to microtubule substrates, complexes with β-catenin to sustain Wnt/c-Myc signaling, interacts with FAK/SRC to activate NF-κB, stabilizes AURKA by inhibiting its ubiquitination, and is transcriptionally controlled by YAP/TEAD, p53, CHOP, and FOXM1 while being subject to ubiquitin-mediated proteasomal degradation by TRIM29."},"narrative":{"mechanistic_narrative":"HMMR/RHAMM is a multifunctional, multispatial protein that couples hyaluronan (HA) signaling at the cell surface to ERK1/2-driven motility and acts intracellularly as a microtubule- and spindle-associated regulator of mitosis [PMID:7508860, PMID:17158951, PMID:12808028]. Extracellularly, RHAMM binds HA through C-terminal B(X7)B motifs that are necessary and sufficient for HA binding, and the same C-terminal region binds heparin [PMID:7508860, PMID:7534313]. On ras-transformed and invasive cells, RHAMM (rather than CD44) is the primary mediator of HA-stimulated locomotion, acting downstream of Ras and TGF-β1 to drive focal adhesion kinase phosphorylation and focal adhesion turnover [PMID:7693717, PMID:7688314, PMID:7541721, PMID:7518470]. Cell-surface RHAMM is required to localize CD44 to the surface and to assemble CD44–ERK1/2 complexes that sustain ERK activity, wound resurfacing, and invasion, with RHAMM acting upstream of MEK–ERK [PMID:17158951, PMID:17392272]. RHAMM functions as a signaling adaptor: cytoplasmic RHAMMv4 co-immunoprecipitates with MEK1 and ERK to control ERK activation, and HA signaling through RHAMM activates PI3K-dependent Rac to drive migration [PMID:9556628, PMID:16934786]. Intracellularly, RHAMM is a microtubule- and actin-associated protein that targets centrosomes and mitotic spindles, co-associating with dynein intermediate chain to stabilize spindle poles [PMID:12808028, PMID:10547355]. It organizes the spindle by cross-linking microtubules in an ERK1/2-dependent manner, localizing TPX2 and active Aurora kinase A, dampening Eg5-mediated forces through inhibitory TPX2–Eg5 complexes, and acting in a PLK1-dependent pathway that localizes active Ran and positions cortical NuMA–dynein to orient spindles [PMID:20558733, PMID:24875404, PMID:29386294, PMID:28994651]. Hmmr knockout causes neonatal lethality with neural spindle-orientation defects and disrupts planar germ cell divisions in the testis, while cytoplasmic RHAMM maintains embryonic stem cell pluripotency via ERK1/2 and Aurora kinase A [PMID:28994651, PMID:27543603, PMID:24019927]. RHAMM expression is transcriptionally controlled by YAP/TEAD, E2F1, CHOP, and p53, and RHAMM protein is degraded by the E3 ligase TRIM29 [PMID:24367099, PMID:25042645, PMID:18971636, PMID:37405956]. Through stabilization of AURKA against ubiquitination, complexation with β-catenin to sustain Wnt/c-Myc signaling, and cytoplasmic FAK/SRC-mediated NF-κB activation, RHAMM promotes tumorigenesis, metastasis, and immune evasion [PMID:36750558, PMID:26825774, PMID:38838151, PMID:35393420].","teleology":[{"year":1994,"claim":"Established the molecular basis of HA recognition by RHAMM, defining a transferable B(X7)B binding motif and placing RHAMM downstream of TGF-β1 and Ras as the primary HA-motility receptor.","evidence":"Site-directed mutagenesis and chimeric rescue of recombinant RHAMM in HA-Sepharose assays; antibody neutralization of HA- and TGF-β1-induced locomotion","pmids":["7508860","7534313","7693717","7688314"],"confidence":"High","gaps":["Structure of the HA-bound B(X7)B region not resolved","Relative contribution of heparin binding to physiological signaling unclear"]},{"year":1994,"claim":"Connected HA/RHAMM engagement to a rapid, transient tyrosine-kinase signaling output controlling focal adhesion dynamics, identifying FAK as a key effector of HA-stimulated motility.","evidence":"Anti-phosphotyrosine immunoblot, vinculin immunofluorescence, antibody microinjection, and tyrosine kinase inhibitors in ras-transformed fibroblasts","pmids":["7518470"],"confidence":"High","gaps":["Direct kinase responsible for FAK phosphorylation not defined","Link between surface RHAMM and intracellular kinase activation not mechanistically resolved at this stage"]},{"year":1995,"claim":"Demonstrated RHAMM is an oncogenic node acting downstream of ras whose perturbation reverses transformation and metastasis, elevating RHAMM from a motility receptor to a transformation effector.","evidence":"Overexpression, dominant-negative suppressor, and antisense in fibroblasts with in vivo metastasis assays and FAK phosphorylation readouts","pmids":["7541721"],"confidence":"High","gaps":["Molecular step by which RHAMM acts downstream of ras not fully defined","Contribution of surface vs intracellular pools to transformation not separated"]},{"year":1996,"claim":"Showed soluble RHAMM controls mitotic entry by destabilizing cdc2 mRNA, linking RHAMM to cell cycle regulation beyond motility.","evidence":"Soluble RHAMM, dominant-negative and antisense perturbation with Cdc2/Cyclin B1 Western blots and mRNA stability assays","pmids":["8666924"],"confidence":"Medium","gaps":["Mechanism connecting RHAMM to mRNA degradation unknown","Single-lab study"]},{"year":1998,"claim":"Identified an intracellular RHAMM isoform (RHAMMv4) functioning as a MEK–ERK adaptor, establishing RHAMM as a cytoplasmic signaling scaffold distinct from its surface role.","evidence":"Confocal/flow localization, co-IP with MEK1 and ERK, dominant-negative and constitutive-activation experiments with ERK kinase assays","pmids":["9556628"],"confidence":"High","gaps":["Direct binding interface to MEK/ERK not mapped at residue level","Whether scaffolding is constitutive or regulated unclear"]},{"year":1999,"claim":"Defined RHAMM as a microtubule- and actin-associated protein, mapping cytoskeletal-binding subdomains and a Ca2+/calmodulin-binding site, revealing a structural role at the cytoskeleton.","evidence":"GFP-fusion deletion mutants, microtubule and actin co-sedimentation, calmodulin-affinity chromatography","pmids":["10547355"],"confidence":"High","gaps":["Functional consequence of calmodulin binding not established","Regulation of microtubule binding during cell cycle not addressed"]},{"year":2003,"claim":"Localized RHAMM to centrosomes and spindle poles via a dynein-interaction domain, establishing its requirement for spindle pole stability and mitotic progression.","evidence":"Immunofluorescence, reciprocal co-IP of dynein IC, deletion mutant domain mapping in Xenopus and HeLa extracts","pmids":["12808028"],"confidence":"High","gaps":["Direct vs dynein-bridged interaction with microtubules not distinguished","Regulation of centrosomal targeting unknown"]},{"year":2006,"claim":"Genetic knockout placed cell-surface Rhamm upstream of CD44–ERK1/2 complex assembly required for wound repair, providing in vivo confirmation of the motogenic axis.","evidence":"Rhamm−/− mice, scratch wound and collagen invasion assays, CD44–ERK co-IP, and rescue by bead-linked Rhamm or active MEK1","pmids":["17158951"],"confidence":"High","gaps":["How surface Rhamm controls CD44 trafficking not defined","Stoichiometry of the CD44–Rhamm–ERK complex unknown"]},{"year":2006,"claim":"Distinguished RHAMM and CD44 signaling outputs in vascular smooth muscle, showing RHAMM drives PI3K–Rac-dependent migration while CD44 controls RhoA.","evidence":"siRNA knockdown, Rho GTPase pull-down assays, PI3K and Rho-kinase inhibitors, migration assays","pmids":["16934786"],"confidence":"Medium","gaps":["Molecular link from RHAMM to PI3K not identified","Single-lab study"]},{"year":2007,"claim":"Extended the CD44–RHAMM–ERK complex to invasive breast cancer dependent on endogenous HA synthesis, and identified a RHAMM–RON tyrosine kinase axis controlling ciliary beat frequency.","evidence":"Co-IP, co-localization, antibody and MEK inhibitor epistasis, HA synthase siRNA; RHAMM–RON co-IP and function-blocking antibodies in airway epithelium","pmids":["17392272","17395888"],"confidence":"High","gaps":["Determinants of complex formation only in invasive cells unknown","RHAMM–RON interaction interface not mapped"]},{"year":2008,"claim":"Linked RHAMM to BRCA1/BARD1 and to p53-dependent transcriptional repression, integrating RHAMM into tumor-suppressor and cell-cycle control networks.","evidence":"Co-IP (RHAMM–BRCA1/BARD1) summarized in review; RHAMM promoter reporter assays in p53-inducible systems with cell-cycle fractionation","pmids":["18354082","18971636"],"confidence":"Medium","gaps":["BRCA1/BARD1 association reported in a review, not original co-IP here","How BRCA1 attenuates spindle activity mechanistically unclear"]},{"year":2010,"claim":"Defined a RHAMM–ERK1/2–MEK1–tubulin complex through a C-terminal leucine zipper and an ERK D-site, establishing that RHAMM controls microtubule stability via localized ERK activity.","evidence":"Rhamm−/− MEFs with active-MEK1 rescue, co-IP/pulldown, in vitro tubulin polymerization, D-site mutant analysis and kinase assays","pmids":["20558733"],"confidence":"High","gaps":["Spatial regulation of ERK activity at the spindle not fully resolved","How tubulin and ERK binding are coordinated unknown"]},{"year":2011,"claim":"Placed RHAMM in a TPX2-coupled negative feedback loop opposing AURKA during epithelial polarization, integrating it with BRCA1-dependent microtubule reorganization.","evidence":"MCF10A 3D polarization with siRNA of BRCA1/RHAMM/AURKA/TPX2 and imaging","pmids":["22110403"],"confidence":"Medium","gaps":["Direct biochemical basis of the RHAMM–TPX2–AURKA feedback not resolved here","Single-lab study"]},{"year":2014,"claim":"Established RHAMM as a spindle-assembly factor required for correct TPX2 localization and localized Aurora kinase A activation, mapping the RHAMM–TPX2 interaction domains.","evidence":"siRNA silencing, live-cell spindle kinetics, pAURKA immunofluorescence, RHAMM–TPX2 co-IP with deletion mapping","pmids":["24875404"],"confidence":"High","gaps":["Whether RHAMM directly stimulates AURKA or acts via TPX2 not resolved","Regulation of complex assembly during mitosis unclear"]},{"year":2014,"claim":"Identified a feed-forward E2F1–RHAMM transcriptional loop driving fibronectin expression and integrin-β1–FAK signaling for tumor cell transendothelial migration.","evidence":"E2F1–RHAMM co-IP, ChIP on RHAMM promoter, fibronectin reporter, transmigration and xenograft assays","pmids":["25042645"],"confidence":"Medium","gaps":["Direct vs indirect co-activation of E2F1 by RHAMM not separated","Single-lab study"]},{"year":2013,"claim":"Connected RHAMM expression to YAP/TEAD and mevalonate-pathway signaling, identifying a transcriptional input from Hippo/statin-sensitive pathways relevant to cancer cell invasion.","evidence":"RHAMM promoter reporter, YAP/TEAD ChIP, YAP siRNA, simvastatin and geranylgeraniol rescue, in vivo invasion assays","pmids":["24367099"],"confidence":"High","gaps":["MST/LATS-independent YAP control mechanism not fully defined","How statin-sensitive geranylgeranylation feeds into YAP not resolved"]},{"year":2013,"claim":"Showed cytoplasmic RHAMM sustains embryonic stem cell pluripotency through ERK1/2 and Aurora kinase A activity, extending its intracellular role to stem cell self-renewal.","evidence":"Hemizygous Hmmr deletion in ESCs, localization, kinase-inhibitor rescue, pluripotency marker analysis","pmids":["24019927"],"confidence":"Medium","gaps":["Direct targets of RHAMM-regulated kinases in pluripotency not identified","Single-lab study"]},{"year":2015,"claim":"Demonstrated a conserved HA/Hmmr/FAK/Src requirement for epicardial EMT and migration in zebrafish heart regeneration, generalizing RHAMM motility signaling to tissue repair.","evidence":"Morpholino Hmmr knockdown, HA synthesis inhibition, FAK/Src inhibitors in a ventricular resection model","pmids":["26156497"],"confidence":"Medium","gaps":["Direct Hmmr–FAK/Src interaction not shown here","Ortholog study; mammalian relevance not tested"]},{"year":2016,"claim":"Established RHAMM-dependent spindle association as essential for planar germ cell divisions, with loss causing germ cell depletion and seminoma, and tied RHAMM expression to CFIm25 polyadenylation control.","evidence":"Rhamm and CFIm25 mouse models, spindle immunofluorescence, human seminoma analysis","pmids":["27543603"],"confidence":"Medium","gaps":["Mechanism linking RHAMM to division-plane orientation in germ cells not fully resolved","Single-lab study"]},{"year":2016,"claim":"Identified a RHAMM–β-catenin complex that stabilizes β-catenin and activates c-Myc, linking HA/RHAMM to Wnt-pathway-driven proliferation.","evidence":"RHAMM–β-catenin co-IP, immunofluorescence, siRNA, c-Myc reporter and proliferation assays","pmids":["26825774"],"confidence":"Medium","gaps":["How RHAMM protects β-catenin from degradation not defined","Single-lab study"]},{"year":2017,"claim":"Defined HMMR's role in spindle positioning via a PLK1-dependent pathway localizing active Ran and cortical NuMA–dynein, with knockout causing neonatal lethality and neural defects.","evidence":"Hmmr-knockout mouse phenotyping, Ran/NuMA/dynein localization, PLK1 epistasis, overexpression phenotypes","pmids":["28994651"],"confidence":"High","gaps":["Direct molecular link from HMMR to PLK1 and Ran not fully mapped","How cortical and pole functions are coordinated unclear"]},{"year":2018,"claim":"Established HMMR as a nonmotor adaptor dampening Eg5 forces through inhibitory TPX2–Eg5 complexes via a Kif15-homologous motif required for kinetochore tension and anaphase entry.","evidence":"siRNA and genomic deletion, live imaging, kinetochore-tension immunofluorescence, Eg5 inhibitor and Kif15 silencing epistasis, motif rescue","pmids":["29386294"],"confidence":"High","gaps":["Direct binding of HMMR to Eg5 vs TPX2-mediated bridging not fully separated","Structural basis of the Kif15-homology motif not resolved"]},{"year":2018,"claim":"Identified mitosis-specific BACH1 phosphorylation as required for its HMMR/CRM1 interaction stabilizing spindle orientation, adding a regulated partner to HMMR's spindle function.","evidence":"SILAC mass spectrometry, BACH1–HMMR co-IP, phosphomutant rescue, spindle orientation imaging","pmids":["29459360"],"confidence":"Medium","gaps":["Direct interface of HMMR–BACH1 not mapped","Single-lab study"]},{"year":2019,"claim":"Showed isoform-specific oncogenic function, with RHAMMB but not RHAMMA driving pancreatic metastasis through EGFR-dependent signaling.","evidence":"RNA-Seq isoform analysis, experimental metastasis models, EGFR knockdown epistasis","pmids":["31072393"],"confidence":"Medium","gaps":["Molecular basis of isoform-specific EGFR coupling unknown","Single-lab study"]},{"year":2020,"claim":"Refined the RHAMM/CD44 interaction as dependent on HA presentation format, with immobilized but not soluble HA upregulating complexation.","evidence":"FRET microscopy and co-IP comparing soluble vs immobilized HA in breast cancer cells","pmids":["33091625"],"confidence":"Medium","gaps":["Mechanism sensing HA presentation geometry unknown","Single-lab study"]},{"year":2020,"claim":"Placed HMMR in an ER-stress circuit, transcriptionally induced by CHOP and degraded by TRIM29, with HMMR promoting autophagic lysosome activity to relieve ER stress in HCC.","evidence":"Co-IP, TRIM29–HMMR ubiquitination assay, CHOP ChIP/reporter, autophagy marker imaging, HBV-transgenic mouse model","pmids":["37405956"],"confidence":"Medium","gaps":["How HMMR promotes autophagic lysosome activity mechanistically unclear","Single-lab study"]},{"year":2022,"claim":"Demonstrated HMMR overexpression cooperates with Brca1 mutation to drive tumorigenesis by activating AURKA, mislocalizing ARPC2, and triggering micronucleation with cGAS-STING and non-canonical NF-κB signaling.","evidence":"Transgenic HMMR-overexpressing mouse mammary epithelium crossed with Brca1 mutant, micronucleus and pathway-activation assays, macrophage histology","pmids":["35393420"],"confidence":"Medium","gaps":["Causal order of cortical ARPC2 loss and micronucleation not fully resolved","Single-lab study"]},{"year":2023,"claim":"Defined positive feedback loops in which HMMR stabilizes AURKA against ubiquitination to drive mTORC2/AKT/E2F1 signaling in prostate cancer, and forms cytoplasmic FAK–SRC complexes activating NF-κB to sustain CD47-mediated immune evasion in liver cancer.","evidence":"HMMR–AURKA and HMMR–FAK–SRC co-IP, ubiquitination assays, ChIP, NF-κB reporters, phagocytosis and anti-PD-1 in vivo models","pmids":["36750558","38838151"],"confidence":"Medium","gaps":["Whether HMMR directly blocks an AURKA E3 ligase not defined","Single-lab studies for each axis"]},{"year":null,"claim":"How the same protein partitions between its extracellular HA-receptor pool and its intracellular spindle/adaptor pools, and what governs this switch, remains unresolved.","evidence":"No timeline study directly resolves the trafficking and regulatory logic that distributes HMMR across surface, cytoplasmic, microtubule, centrosomal, and mitochondrial pools","pmids":[],"confidence":"Low","gaps":["No structural model of full-length HMMR or its bound complexes","Mechanism partitioning HMMR between surface and intracellular pools unknown","Direct vs scaffold-bridged nature of many reported interactions undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[7,15,9,18,23]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[8,9,15]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[18,23,31]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[19,29]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[10,7,11,30]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[7,15,29,32]},{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[8,9,15]},{"term_id":"GO:0005815","term_label":"microtubule organizing center","supporting_discovery_ids":[9,22]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,6]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[26]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[9,18,22,23]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,10,11,13,15]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,27,31,32,34]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[17,19,25,33]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[32,27]}],"complexes":["CD44–RHAMM–ERK1/2 complex","RHAMM–ERK1/2–MEK1–tubulin complex","RHAMM–TPX2 (and TPX2–Eg5) spindle complex","HMMR–FAK–SRC cytoplasmic complex"],"partners":["CD44","ERK1/2","MEK1","TPX2","AURKA","DYNC1I (DYNEIN INTERMEDIATE CHAIN)","BACH1","CTNNB1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O75330","full_name":"Hyaluronan mediated motility receptor","aliases":["Intracellular hyaluronic acid-binding protein","Receptor for hyaluronan-mediated motility"],"length_aa":724,"mass_kda":84.1,"function":"Receptor for hyaluronic acid (HA) (By similarity). Involved in cell motility (By similarity). When hyaluronan binds to HMMR, the phosphorylation of a number of proteins, including PTK2/FAK1 occurs. May also be involved in cellular transformation and metastasis formation, and in regulating extracellular-regulated kinase (ERK) activity. May act as a regulator of adipogenisis (By similarity)","subcellular_location":"Cell surface; Cytoplasm; Cytoplasm, cytoskeleton, spindle","url":"https://www.uniprot.org/uniprotkb/O75330/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/HMMR","classification":"Not Classified","n_dependent_lines":12,"n_total_lines":1208,"dependency_fraction":0.009933774834437087},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"DYNLL2","stoichiometry":10.0},{"gene":"CSNK1A1","stoichiometry":4.0},{"gene":"DYNLL1","stoichiometry":0.2},{"gene":"TUBB4B","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/HMMR","total_profiled":1310},"omim":[{"mim_id":"617569","title":"KINESIN FAMILY, MEMBER 15; KIF15","url":"https://www.omim.org/entry/617569"},{"mim_id":"611814","title":"ELONGATION OF VERY LONG CHAIN FATTY ACIDS-LIKE 2; ELOVL2","url":"https://www.omim.org/entry/611814"},{"mim_id":"600936","title":"HYALURONAN-MEDIATED MOTILITY RECEPTOR; HMMR","url":"https://www.omim.org/entry/600936"},{"mim_id":"114480","title":"BREAST CANCER","url":"https://www.omim.org/entry/114480"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Microtubules","reliability":"Enhanced"},{"location":"Centrosome","reliability":"Additional"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"bone marrow","ntpm":19.4},{"tissue":"lymphoid tissue","ntpm":25.4},{"tissue":"testis","ntpm":25.7}],"url":"https://www.proteinatlas.org/search/HMMR"},"hgnc":{"alias_symbol":["RHAMM","CD168"],"prev_symbol":[]},"alphafold":{"accession":"O75330","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O75330","model_url":"https://alphafold.ebi.ac.uk/files/AF-O75330-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O75330-F1-predicted_aligned_error_v6.png","plddt_mean":74.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=HMMR","jax_strain_url":"https://www.jax.org/strain/search?query=HMMR"},"sequence":{"accession":"O75330","fasta_url":"https://rest.uniprot.org/uniprotkb/O75330.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O75330/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O75330"}},"corpus_meta":[{"pmid":"25999946","id":"PMC_25999946","title":"Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer.","date":"2015","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25999946","citation_count":668,"is_preprint":false},{"pmid":"7508860","id":"PMC_7508860","title":"Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein.","date":"1994","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/7508860","citation_count":355,"is_preprint":false},{"pmid":"17055233","id":"PMC_17055233","title":"Hyaluronan-mediated angiogenesis in vascular disease: uncovering RHAMM and CD44 receptor signaling pathways.","date":"2006","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/17055233","citation_count":344,"is_preprint":false},{"pmid":"24367099","id":"PMC_24367099","title":"Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24367099","citation_count":278,"is_preprint":false},{"pmid":"7541721","id":"PMC_7541721","title":"Overexpression of the hyaluronan receptor RHAMM is transforming and is also required for H-ras transformation.","date":"1995","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/7541721","citation_count":252,"is_preprint":false},{"pmid":"17392272","id":"PMC_17392272","title":"The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17392272","citation_count":216,"is_preprint":false},{"pmid":"7518470","id":"PMC_7518470","title":"Hyaluronan and the hyaluronan receptor RHAMM promote focal adhesion turnover and transient tyrosine kinase activity.","date":"1994","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7518470","citation_count":212,"is_preprint":false},{"pmid":"18354082","id":"PMC_18354082","title":"Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions?","date":"2008","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/18354082","citation_count":191,"is_preprint":false},{"pmid":"9556628","id":"PMC_9556628","title":"The hyaluronan receptor RHAMM regulates extracellular-regulated kinase.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9556628","citation_count":185,"is_preprint":false},{"pmid":"10547355","id":"PMC_10547355","title":"The intracellular hyaluronan receptor RHAMM/IHABP interacts with microtubules and actin filaments.","date":"1999","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/10547355","citation_count":154,"is_preprint":false},{"pmid":"12808028","id":"PMC_12808028","title":"RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability.","date":"2003","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/12808028","citation_count":150,"is_preprint":false},{"pmid":"17158951","id":"PMC_17158951","title":"Rhamm-/- fibroblasts are defective in CD44-mediated ERK1,2 motogenic signaling, leading to defective skin wound repair.","date":"2006","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17158951","citation_count":129,"is_preprint":false},{"pmid":"7693717","id":"PMC_7693717","title":"TGF-beta 1 stimulation of cell locomotion utilizes the hyaluronan receptor RHAMM and hyaluronan.","date":"1993","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/7693717","citation_count":127,"is_preprint":false},{"pmid":"24710409","id":"PMC_24710409","title":"HMMR maintains the stemness and tumorigenicity of glioblastoma stem-like cells.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24710409","citation_count":111,"is_preprint":false},{"pmid":"8666924","id":"PMC_8666924","title":"Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression.","date":"1996","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8666924","citation_count":105,"is_preprint":false},{"pmid":"19724912","id":"PMC_19724912","title":"Oligosaccharides of hyaluronan induce angiogenesis through distinct CD44 and RHAMM-mediated signalling pathways involving Cdc2 and gamma-adducin.","date":"2009","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19724912","citation_count":104,"is_preprint":false},{"pmid":"22889846","id":"PMC_22889846","title":"A RHAMM mimetic peptide blocks hyaluronan signaling and reduces inflammation and fibrogenesis in excisional skin wounds.","date":"2012","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/22889846","citation_count":104,"is_preprint":false},{"pmid":"25157350","id":"PMC_25157350","title":"Hyaluronan and RHAMM in wound repair and the \"cancerization\" of stromal tissues.","date":"2014","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/25157350","citation_count":103,"is_preprint":false},{"pmid":"9601098","id":"PMC_9601098","title":"The human hyaluronan receptor RHAMM is expressed as an intracellular protein in breast cancer cells.","date":"1998","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/9601098","citation_count":101,"is_preprint":false},{"pmid":"15827130","id":"PMC_15827130","title":"Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15827130","citation_count":98,"is_preprint":false},{"pmid":"16037485","id":"PMC_16037485","title":"Expression and role of the hyaluronan receptor RHAMM in inflammation after bleomycin injury.","date":"2005","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16037485","citation_count":95,"is_preprint":false},{"pmid":"16934786","id":"PMC_16934786","title":"Hyaluronan induces vascular smooth muscle cell migration through RHAMM-mediated PI3K-dependent Rac activation.","date":"2006","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/16934786","citation_count":92,"is_preprint":false},{"pmid":"18971636","id":"PMC_18971636","title":"RHAMM is differentially expressed in the cell cycle and downregulated by the tumor suppressor p53.","date":"2008","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/18971636","citation_count":91,"is_preprint":false},{"pmid":"17395888","id":"PMC_17395888","title":"Apical oxidative hyaluronan degradation stimulates airway ciliary beating via RHAMM and RON.","date":"2007","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17395888","citation_count":91,"is_preprint":false},{"pmid":"22110403","id":"PMC_22110403","title":"Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.","date":"2011","source":"PLoS biology","url":"https://pubmed.ncbi.nlm.nih.gov/22110403","citation_count":88,"is_preprint":false},{"pmid":"10029598","id":"PMC_10029598","title":"Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants.","date":"1999","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/10029598","citation_count":84,"is_preprint":false},{"pmid":"14534534","id":"PMC_14534534","title":"Genetic deletion of receptor for hyaluronan-mediated motility (Rhamm) attenuates the formation of aggressive fibromatosis (desmoid tumor).","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/14534534","citation_count":82,"is_preprint":false},{"pmid":"7529076","id":"PMC_7529076","title":"RHAMM, a receptor for hyaluronan-mediated motility, on normal human lymphocytes, thymocytes and malignant B cells: a mediator in B cell malignancy?","date":"1994","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/7529076","citation_count":81,"is_preprint":false},{"pmid":"20558733","id":"PMC_20558733","title":"RHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20558733","citation_count":80,"is_preprint":false},{"pmid":"26156497","id":"PMC_26156497","title":"Extracellular component hyaluronic acid and its receptor Hmmr are required for epicardial EMT during heart regeneration.","date":"2015","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/26156497","citation_count":76,"is_preprint":false},{"pmid":"11029494","id":"PMC_11029494","title":"Expression of hyaluronan receptors CD44 and RHAMM in stomach cancers: relevance with tumor progression.","date":"2000","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11029494","citation_count":76,"is_preprint":false},{"pmid":"32231069","id":"PMC_32231069","title":"Hyaluronan Mediated Motility Receptor (HMMR) Encodes an Evolutionarily Conserved Homeostasis, Mitosis, and Meiosis Regulator Rather than a Hyaluronan Receptor.","date":"2020","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/32231069","citation_count":69,"is_preprint":false},{"pmid":"19724689","id":"PMC_19724689","title":"RHAMM (CD168) is overexpressed at the protein level and may constitute an immunogenic antigen in advanced prostate cancer disease.","date":"2009","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/19724689","citation_count":69,"is_preprint":false},{"pmid":"8750188","id":"PMC_8750188","title":"Hyaluronan: RHAMM mediated cell locomotion and signaling in tumorigenesis.","date":"1995","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/8750188","citation_count":68,"is_preprint":false},{"pmid":"8634437","id":"PMC_8634437","title":"Hyaluronan-dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma: alternate use of receptor for hyaluronan-mediated motility (RHAMM) and CD44.","date":"1996","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/8634437","citation_count":68,"is_preprint":false},{"pmid":"30365189","id":"PMC_30365189","title":"Hyaluronan-CD44/RHAMM interaction-dependent cell proliferation and survival in lung cancer cells.","date":"2018","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/30365189","citation_count":67,"is_preprint":false},{"pmid":"32559619","id":"PMC_32559619","title":"HCG18/miR-34a-5p/HMMR axis accelerates the progression of lung adenocarcinoma.","date":"2020","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/32559619","citation_count":67,"is_preprint":false},{"pmid":"7688314","id":"PMC_7688314","title":"Ras-transformed cells express both CD44 and RHAMM hyaluronan receptors: only RHAMM is essential for hyaluronan-promoted locomotion.","date":"1993","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/7688314","citation_count":67,"is_preprint":false},{"pmid":"35179300","id":"PMC_35179300","title":"Exosomal lncRNA HMMR-AS1 mediates macrophage polarization through miR-147a/ARID3A axis under hypoxia and affects the progression of hepatocellular carcinoma.","date":"2022","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/35179300","citation_count":66,"is_preprint":false},{"pmid":"11592098","id":"PMC_11592098","title":"The pattern of expression of the microtubule-binding protein RHAMM/IHABP in mammary carcinoma suggests a role in the invasive behaviour of tumour cells.","date":"2001","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11592098","citation_count":66,"is_preprint":false},{"pmid":"30130585","id":"PMC_30130585","title":"Hyaluronic acid, CD44 and RHAMM regulate myoblast behavior during embryogenesis.","date":"2018","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30130585","citation_count":65,"is_preprint":false},{"pmid":"16773189","id":"PMC_16773189","title":"Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia.","date":"2006","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16773189","citation_count":62,"is_preprint":false},{"pmid":"9816340","id":"PMC_9816340","title":"Differential expression of the hyaluronan receptors CD44 and RHAMM in human pancreatic cancer cells.","date":"1996","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/9816340","citation_count":61,"is_preprint":false},{"pmid":"24083250","id":"PMC_24083250","title":"The roles of hyaluronan/RHAMM/CD44 and their respective interactions along the insidious pathways of fibrosarcoma progression.","date":"2013","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/24083250","citation_count":57,"is_preprint":false},{"pmid":"20956971","id":"PMC_20956971","title":"RHAMM/ERK interaction induces proliferative activities of cementifying fibroma cells through a mechanism based on the CD44-EGFR.","date":"2010","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/20956971","citation_count":56,"is_preprint":false},{"pmid":"22371883","id":"PMC_22371883","title":"TCR-transgenic lymphocytes specific for HMMR/Rhamm limit tumor outgrowth in vivo.","date":"2012","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/22371883","citation_count":53,"is_preprint":false},{"pmid":"29050306","id":"PMC_29050306","title":"The hyaluronan-mediated motility receptor RHAMM promotes growth, invasiveness and dissemination of colorectal cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29050306","citation_count":51,"is_preprint":false},{"pmid":"31128573","id":"PMC_31128573","title":"LncRNA HMMR-AS1 promotes proliferation and metastasis of lung adenocarcinoma by regulating MiR-138/sirt6 axis.","date":"2019","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/31128573","citation_count":49,"is_preprint":false},{"pmid":"28994651","id":"PMC_28994651","title":"HMMR acts in the PLK1-dependent spindle positioning pathway and supports neural development.","date":"2017","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/28994651","citation_count":49,"is_preprint":false},{"pmid":"30098420","id":"PMC_30098420","title":"The Receptor for Hyaluronan-Mediated Motility (CD168) promotes inflammation and fibrosis after acute lung injury.","date":"2018","source":"Matrix biology : journal of the International Society for Matrix Biology","url":"https://pubmed.ncbi.nlm.nih.gov/30098420","citation_count":46,"is_preprint":false},{"pmid":"29574252","id":"PMC_29574252","title":"Targeting Long Noncoding RNA HMMR-AS1 Suppresses and Radiosensitizes Glioblastoma.","date":"2018","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/29574252","citation_count":45,"is_preprint":false},{"pmid":"7531178","id":"PMC_7531178","title":"Astrocyte and microglial motility in vitro is functionally dependent on the hyaluronan receptor RHAMM.","date":"1994","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/7531178","citation_count":44,"is_preprint":false},{"pmid":"33091625","id":"PMC_33091625","title":"Co-localization and crosstalk between CD44 and RHAMM depend on hyaluronan presentation.","date":"2020","source":"Acta biomaterialia","url":"https://pubmed.ncbi.nlm.nih.gov/33091625","citation_count":41,"is_preprint":false},{"pmid":"24875404","id":"PMC_24875404","title":"Spatial regulation of Aurora A activity during mitotic spindle assembly requires RHAMM to correctly localize TPX2.","date":"2014","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/24875404","citation_count":41,"is_preprint":false},{"pmid":"28529647","id":"PMC_28529647","title":"Redox Responsive Hyaluronic Acid Nanogels for Treating RHAMM (CD168) Over-expressive Cancer, both Primary and Metastatic Tumors.","date":"2017","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/28529647","citation_count":40,"is_preprint":false},{"pmid":"25830658","id":"PMC_25830658","title":"Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers.","date":"2015","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25830658","citation_count":40,"is_preprint":false},{"pmid":"37001272","id":"PMC_37001272","title":"Resveratrol improves the cytotoxic effect of CD8 +T cells in the tumor microenvironment by regulating HMMR/Ferroptosis in lung squamous cell carcinoma.","date":"2023","source":"Journal of pharmaceutical and biomedical analysis","url":"https://pubmed.ncbi.nlm.nih.gov/37001272","citation_count":40,"is_preprint":false},{"pmid":"23391595","id":"PMC_23391595","title":"Selective expression of hyaluronan and receptor for hyaluronan mediated motility (Rhamm) in the adult mouse subventricular zone and rostral migratory stream and in ischemic cortex.","date":"2013","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/23391595","citation_count":40,"is_preprint":false},{"pmid":"35393420","id":"PMC_35393420","title":"Modification of BRCA1-associated breast cancer risk by HMMR overexpression.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35393420","citation_count":39,"is_preprint":false},{"pmid":"25042645","id":"PMC_25042645","title":"Association of RHAMM with E2F1 promotes tumour cell extravasation by transcriptional up-regulation of fibronectin.","date":"2014","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25042645","citation_count":39,"is_preprint":false},{"pmid":"31072393","id":"PMC_31072393","title":"Function and clinical relevance of RHAMM isoforms in pancreatic tumor progression.","date":"2019","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/31072393","citation_count":38,"is_preprint":false},{"pmid":"26351067","id":"PMC_26351067","title":"Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers.","date":"2015","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26351067","citation_count":38,"is_preprint":false},{"pmid":"7534313","id":"PMC_7534313","title":"Identification of a novel heparin binding domain in RHAMM and evidence that it modifies HA mediated locomotion of ras-transformed cells.","date":"1994","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7534313","citation_count":38,"is_preprint":false},{"pmid":"18356573","id":"PMC_18356573","title":"A putative role for RHAMM/HMMR as a negative marker of stem cell-containing population of human limbal epithelial cells.","date":"2008","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/18356573","citation_count":36,"is_preprint":false},{"pmid":"31988250","id":"PMC_31988250","title":"TGFβ and Hippo Pathways Cooperate to Enhance Sarcomagenesis and Metastasis through the Hyaluronan-Mediated Motility Receptor (HMMR).","date":"2020","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/31988250","citation_count":34,"is_preprint":false},{"pmid":"34638654","id":"PMC_34638654","title":"RHAMM Is a Multifunctional Protein That Regulates Cancer Progression.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34638654","citation_count":33,"is_preprint":false},{"pmid":"11433424","id":"PMC_11433424","title":"Subcellular distribution, calmodulin interaction, and mitochondrial association of the hyaluronan-binding protein RHAMM in rat brain.","date":"2001","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/11433424","citation_count":32,"is_preprint":false},{"pmid":"36033439","id":"PMC_36033439","title":"The role of RHAMM in cancer: Exposing novel therapeutic vulnerabilities.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36033439","citation_count":31,"is_preprint":false},{"pmid":"24676428","id":"PMC_24676428","title":"Role of receptor for hyaluronan-mediated motility (RHAMM) in human head and neck cancers.","date":"2014","source":"Journal of cancer research and clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/24676428","citation_count":31,"is_preprint":false},{"pmid":"28954627","id":"PMC_28954627","title":"Increased RHAMM expression relates to ovarian cancer progression.","date":"2017","source":"Journal of ovarian research","url":"https://pubmed.ncbi.nlm.nih.gov/28954627","citation_count":31,"is_preprint":false},{"pmid":"12469144","id":"PMC_12469144","title":"Differential expression patterns of hyaluronan receptors CD44 and RHAMM in transitional cell carcinomas of urinary bladder.","date":"2003","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/12469144","citation_count":31,"is_preprint":false},{"pmid":"25081535","id":"PMC_25081535","title":"Hyaluronan/RHAMM interactions in mesenchymal tumor pathogenesis: role of growth factors.","date":"2014","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/25081535","citation_count":31,"is_preprint":false},{"pmid":"28217782","id":"PMC_28217782","title":"Receptor for hyaluronan mediated motility (RHAMM/HMMR) is a novel target for promoting subcutaneous adipogenesis.","date":"2017","source":"Integrative biology : quantitative biosciences from nano to macro","url":"https://pubmed.ncbi.nlm.nih.gov/28217782","citation_count":30,"is_preprint":false},{"pmid":"22666460","id":"PMC_22666460","title":"ANKRD26 and its interacting partners TRIO, GPS2, HMMR and DIPA regulate adipogenesis in 3T3-L1 cells.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22666460","citation_count":30,"is_preprint":false},{"pmid":"26825774","id":"PMC_26825774","title":"Receptor for hyaluronic acid- mediated motility (RHAMM) regulates HT1080 fibrosarcoma cell proliferation via a β-catenin/c-myc signaling axis.","date":"2016","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/26825774","citation_count":30,"is_preprint":false},{"pmid":"22532518","id":"PMC_22532518","title":"RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia.","date":"2012","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/22532518","citation_count":29,"is_preprint":false},{"pmid":"20044037","id":"PMC_20044037","title":"RHAMM mRNA expression in proliferating and migrating cells of the developing central nervous system.","date":"2010","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/20044037","citation_count":29,"is_preprint":false},{"pmid":"37405956","id":"PMC_37405956","title":"HMMR alleviates endoplasmic reticulum stress by promoting autophagolysosomal activity during endoplasmic reticulum stress-driven hepatocellular carcinoma progression.","date":"2023","source":"Cancer communications (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/37405956","citation_count":28,"is_preprint":false},{"pmid":"23328114","id":"PMC_23328114","title":"Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.","date":"2013","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/23328114","citation_count":28,"is_preprint":false},{"pmid":"27543603","id":"PMC_27543603","title":"Impaired Planar Germ Cell Division in the Testis, Caused by Dissociation of RHAMM from the Spindle, Results in Hypofertility and Seminoma.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27543603","citation_count":28,"is_preprint":false},{"pmid":"37929733","id":"PMC_37929733","title":"FIGNL1 Promotes Hepatocellular Carcinoma Formation via Remodeling ECM-receptor Interaction Pathway Mediated by HMMR.","date":"2024","source":"Current gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37929733","citation_count":26,"is_preprint":false},{"pmid":"33061798","id":"PMC_33061798","title":"Oleate acid-stimulated HMMR expression by CEBPα is associated with nonalcoholic steatohepatitis and hepatocellular carcinoma.","date":"2020","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33061798","citation_count":25,"is_preprint":false},{"pmid":"12493696","id":"PMC_12493696","title":"Developmental regulation of hyaluronan-binding protein (RHAMM/IHABP) expression in early bovine embryos.","date":"2003","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/12493696","citation_count":25,"is_preprint":false},{"pmid":"36750558","id":"PMC_36750558","title":"HMMR promotes prostate cancer proliferation and metastasis via AURKA/mTORC2/E2F1 positive feedback loop.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/36750558","citation_count":24,"is_preprint":false},{"pmid":"27595989","id":"PMC_27595989","title":"CD44 and RHAMM are essential for rapid growth of bladder cancer driven by loss of Glycogen Debranching Enzyme (AGL).","date":"2016","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/27595989","citation_count":24,"is_preprint":false},{"pmid":"17009043","id":"PMC_17009043","title":"Imatinib impairs CD8+ T lymphocytes specifically directed against the leukemia-associated antigen RHAMM/CD168 in vitro.","date":"2006","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/17009043","citation_count":23,"is_preprint":false},{"pmid":"27920576","id":"PMC_27920576","title":"HMMR antisense RNA 1, a novel long noncoding RNA, regulates the progression of basal-like breast cancer cells.","date":"2016","source":"Breast cancer (Dove Medical Press)","url":"https://pubmed.ncbi.nlm.nih.gov/27920576","citation_count":23,"is_preprint":false},{"pmid":"34044069","id":"PMC_34044069","title":"High levels of truncated RHAMM cooperate with dysfunctional p53 to accelerate the progression of pancreatic cancer.","date":"2021","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/34044069","citation_count":23,"is_preprint":false},{"pmid":"38838151","id":"PMC_38838151","title":"HMMR triggers immune evasion of hepatocellular carcinoma by inactivation of phagocyte killing.","date":"2024","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/38838151","citation_count":22,"is_preprint":false},{"pmid":"18174258","id":"PMC_18174258","title":"Androgen receptor regulates CD168 expression and signaling in prostate cancer.","date":"2008","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/18174258","citation_count":22,"is_preprint":false},{"pmid":"32165498","id":"PMC_32165498","title":"Cell-specific expression of the transcriptional regulator RHAMM provides a timing mechanism that controls appropriate wound re-epithelialization.","date":"2020","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32165498","citation_count":22,"is_preprint":false},{"pmid":"24019927","id":"PMC_24019927","title":"The cytoskeletal protein RHAMM and ERK1/2 activity maintain the pluripotency of murine embryonic stem cells.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24019927","citation_count":22,"is_preprint":false},{"pmid":"29212185","id":"PMC_29212185","title":"Hyaluronic acid enhances cell migration and invasion via the YAP1/TAZ-RHAMM axis in malignant pleural mesothelioma.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29212185","citation_count":22,"is_preprint":false},{"pmid":"29459360","id":"PMC_29459360","title":"Phosphorylation of BACH1 switches its function from transcription factor to mitotic chromosome regulator and promotes its interaction with HMMR.","date":"2018","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/29459360","citation_count":22,"is_preprint":false},{"pmid":"35456219","id":"PMC_35456219","title":"Serum Proteins, HMMR, NXPH4, PITX1 and THBS4; A Panel of Biomarkers for Early Diagnosis of Hepatocellular Carcinoma.","date":"2022","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35456219","citation_count":21,"is_preprint":false},{"pmid":"21947782","id":"PMC_21947782","title":"Overexpression of receptor for hyaluronan-mediated motility (RHAMM) in MC3T3-E1 cells induces proliferation and differentiation through phosphorylation of ERK1/2.","date":"2011","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/21947782","citation_count":21,"is_preprint":false},{"pmid":"34624323","id":"PMC_34624323","title":"HMMR is a downstream target of FOXM1 in enhancing proliferation and partial epithelial-to-mesenchymal transition of bladder cancer cells.","date":"2021","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34624323","citation_count":20,"is_preprint":false},{"pmid":"29386294","id":"PMC_29386294","title":"The nonmotor adaptor HMMR dampens Eg5-mediated forces to preserve the kinetics and integrity of chromosome segregation.","date":"2018","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/29386294","citation_count":20,"is_preprint":false},{"pmid":"27659531","id":"PMC_27659531","title":"The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27659531","citation_count":19,"is_preprint":false},{"pmid":"8595891","id":"PMC_8595891","title":"The human and mouse receptors for hyaluronan-mediated motility, RHAMM, genes (HMMR) map to human chromosome 5q33.2-qter and mouse chromosome 11.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8595891","citation_count":19,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":52552,"output_tokens":10710,"usd":0.159153,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":21531,"output_tokens":8835,"usd":0.164265,"stage2_stop_reason":"end_turn"},"total_usd":0.323418,"stage1_batch_id":"msgbatch_01DUPACZi7AAWwuZiUjseQF4","stage2_batch_id":"msgbatch_018yt7chE3f48PEFtDwtj6AE","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"RHAMM contains two HA-binding domains near the C-terminus defined by a B(X7)B motif (two basic amino acids flanking a seven-amino-acid stretch). Site-directed mutagenesis of K423, R431, and adjacent basic residues abolished HA binding; mutation of all B(X7)B motifs in recombinant RHAMM eliminated HA binding entirely. The same motif, when grafted onto the non-binding N-terminus of RHAMM, conferred HA binding, confirming this motif is necessary and sufficient for HA binding in RHAMM, CD44, and link protein.\",\n      \"method\": \"Site-directed mutagenesis of recombinant RHAMM fusion proteins, HA-Sepharose binding assays, chimeric protein construction, transblot analysis\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution with recombinant proteins, mutagenesis of specific residues, chimeric rescue experiments, replicated across multiple constructs in one rigorous study\",\n      \"pmids\": [\"7508860\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"RHAMM also contains a heparin-binding domain co-localizing with the HA-binding B(X7)B region at the C-terminus. Heparin at physiological concentrations (0.1 mg/ml) stimulated cell locomotion in a RHAMM-dependent manner (blocked by anti-RHAMM antibodies), while low concentrations (0.01 mg/ml) inhibited HA-induced locomotion independently of RHAMM. GST-RHAMM fusion protein bound biotin-labeled heparin in ligand blotting assays; deletion of HA-binding domains abolished heparin binding.\",\n      \"method\": \"Ligand blotting, HA-Sepharose/HP-Sepharose affinity chromatography, deletion analysis of fusion proteins, antibody neutralization of cell locomotion\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro binding assays with recombinant proteins and deletion mutants, functional locomotion assays; single lab\",\n      \"pmids\": [\"7534313\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"HA stimulation of ras-transformed fibroblast motility via RHAMM promotes rapid, transient protein tyrosine phosphorylation (within 1 min, dissipating by 10–15 min) and focal adhesion kinase (pp125FAK) phosphorylation/dephosphorylation, accompanied by rapid assembly and disassembly of focal adhesions (monitored by vinculin immunofluorescence). Tyrosine kinase inhibitors and microinjected anti-phosphotyrosine antibodies blocked both the phosphorylation and HA-stimulated motility. Anti-RHAMM antibodies reproduced the same tyrosine phosphorylation and focal adhesion turnover as HA.\",\n      \"method\": \"Immunoblot with anti-phosphotyrosine antibodies, immunofluorescence of vinculin, microinjection of antibodies, tyrosine kinase inhibitors (genistein, herbimycin A), time-course kinase assay\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (immunoblot, immunofluorescence, microinjection, pharmacological inhibition), consistent results across approaches, foundational mechanism paper\",\n      \"pmids\": [\"7518470\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"TGF-β1 stimulates cell locomotion by inducing transcription, synthesis, and membrane expression of RHAMM and coincident HA secretion. Anti-RHAMM antibodies and RHAMM HA-binding domain peptides suppressed TGF-β1-induced motility, placing RHAMM downstream of TGF-β1 in the motility pathway.\",\n      \"method\": \"Antibody neutralization, antisense oligonucleotides, exogenous TGF-β1 treatment, anti-RHAMM peptides, TGF-β1-transfected cell models\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional epistasis via multiple inhibitory approaches; single lab\",\n      \"pmids\": [\"7693717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"On ras-transformed fibroblasts, RHAMM (not CD44) is the primary mediator of HA-promoted cell locomotion. Anti-RHAMM antibodies completely inhibited HA-stimulated locomotion, whereas multiple anti-CD44 antibodies that block HA/CD44 interactions had no effect on locomotory responses to HA.\",\n      \"method\": \"Antibody neutralization assays, transblot HA-binding assay comparing CD44 and RHAMM, time-lapse locomotion assays\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional antibody neutralization with multiple anti-CD44 clones as controls; single lab\",\n      \"pmids\": [\"7688314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Overexpression of RHAMM transforms fibroblasts and causes spontaneous lung metastases. A dominant-suppressor RHAMM mutant reverses H-ras transformation and tumorigenicity; antisense reduction of RHAMM renders fibroblasts resistant to ras transformation. RHAMM acts downstream of ras, and loss of functional RHAMM ablates focal adhesion kinase (FAK) phosphorylation changes and prevents focal adhesion turnover in response to HA.\",\n      \"method\": \"Transfection overexpression, dominant-negative suppressor mutant, antisense transfection, in vivo tumor/metastasis assay, focal adhesion kinase phosphorylation analysis\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (dominant-negative + antisense + overexpression), in vivo tumor models, FAK phosphorylation readout; landmark study with multiple orthogonal approaches\",\n      \"pmids\": [\"7541721\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Soluble RHAMM induces G2/M cell cycle arrest by suppressing Cdc2/Cyclin B1 expression through increased cdc2 mRNA degradation. Dominant-negative RHAMM mutants and antisense mRNA knockdown also decreased Cdc2 protein levels, linking RHAMM to mitotic entry control.\",\n      \"method\": \"Soluble RHAMM protein treatment, dominant-negative mutants, antisense knockdown, Western blot for Cdc2/Cyclin B1, mRNA stability assay, in vivo metastasis assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple genetic approaches to perturb RHAMM, mRNA degradation assay; single lab\",\n      \"pmids\": [\"8666924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"RHAMM isoforms differ in subcellular localization: isoforms encoding exon 4 occur on the cell surface and in the cytoplasm; RHAMMv4 (encoding exon 4) is exclusively cytoplasmic. Intracellular RHAMMv4 regulates ERK1/2 activity: anti-RHAMM exon 4 antibodies block PDGF-induced ERK activation; a dominant-negative RHAMMv4 inhibits mutant active Ras-stimulated ERK activation and co-immunoprecipitates with MEK1 and ERK, indicating RHAMMv4 acts as an adaptor at the MEK–ERK level. Overexpression of RHAMMv4 constitutively activates ERK.\",\n      \"method\": \"Flow cytometry, confocal microscopy, epitope-tagging, co-immunoprecipitation with MEK1/ERK, dominant-negative expression, ERK kinase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — co-IP of MEK1/ERK complex, dominant-negative epistasis, constitutive activation overexpression, localization by flow cytometry and confocal; multiple orthogonal methods in one study\",\n      \"pmids\": [\"9556628\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Intracellular RHAMM/IHABP co-localizes with microtubules in interphase and dividing cells and is a novel microtubule-associated protein (MAP). Microtubule-binding region was mapped to the extreme N-terminus using deletion mutants fused to GFP; two subdomains are required for interphase microtubule binding, while one subdomain is sufficient for mitotic spindle binding. RHAMM/IHABP also interacts with actin filaments in vivo and in vitro. A calmodulin-binding site within residues 574–602 mediates Ca2+-dependent calmodulin binding.\",\n      \"method\": \"GFP fusion protein expression, microtubule co-sedimentation/binding assays, deletion mutant transfection, in vitro actin co-sedimentation, calmodulin-affinity chromatography\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — in vitro binding assays with deletion mutants, GFP co-localization, calmodulin affinity chromatography; multiple orthogonal methods in one study\",\n      \"pmids\": [\"10547355\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"RHAMM localizes to centrosomes and is required for spindle pole stability. The N-terminus binds microtubules, while a separate C-terminal domain (72% identical to the dynein-interaction domain of Xklp2) is required for centrosomal targeting. Anti-RHAMM antibodies co-immunoprecipitate dynein intermediate chain (dynein IC) from Xenopus and HeLa extracts. Deregulation of RHAMM expression inhibits mitotic progression and disrupts spindle architecture.\",\n      \"method\": \"Immunofluorescence, co-immunoprecipitation of dynein IC, deletion mutant analysis, overexpression/knockdown cell biology, phylogenetic analysis\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP with dynein, domain mapping with deletion mutants, centrosomal localization confirmed by immunofluorescence, functional deregulation phenotype; multiple methods in one study\",\n      \"pmids\": [\"12808028\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Cell surface Rhamm is required for localization of CD44 to the cell surface, formation of CD44–ERK1,2 complexes, and nuclear targeting of activated ERK1,2 in fibroblasts. Rhamm−/− fibroblasts fail to resurface scratch wounds or invade HA-supplemented collagen gels; these defects are rescued by cell-surface-restricted recombinant Rhamm (bead-linked) or by expression of constitutively active MEK1, establishing that Rhamm acts upstream of ERK1,2 in this motogenic pathway. ERK1,2 activation and fibroblast migration/differentiation are also defective during skin wound repair in vivo in Rhamm−/− mice.\",\n      \"method\": \"Rhamm−/− genetic knockout mice, scratch wound assay, collagen gel invasion, co-immunoprecipitation (CD44–ERK1,2), subcellular fractionation, bead-linked recombinant Rhamm rescue, mutant active MEK1 rescue, in vivo excisional wound model\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with in vitro and in vivo phenotypes, reciprocal co-IP, mechanistic rescue experiments with both recombinant protein and active MEK1; multiple orthogonal methods\",\n      \"pmids\": [\"17158951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Cell surface Rhamm and CD44 form a complex with ERK1,2 that sustains high basal ERK1,2 activity and motility in invasive breast cancer cells, dependent on endogenous hyaluronan synthesis. CD44, Rhamm, and ERK1,2 uniquely co-immunoprecipitate and co-localize in invasive MDA-MB-231 and Ras-MCF10A cells but not in less invasive lines. Combined anti-CD44 + anti-Rhamm antibodies and MEK1 inhibitor showed less-than-additive effects, indicating action on a common pathway.\",\n      \"method\": \"Co-immunoprecipitation, co-localization by immunofluorescence, antibody neutralization, MEK1 inhibitor (PD098059), siRNA knockdown of HA synthase\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal co-IP, co-localization, pharmacological epistasis, HA synthesis inhibition; multiple orthogonal methods in one study\",\n      \"pmids\": [\"17392272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"RHAMM physically associates with the receptor tyrosine kinase RON (recepteur d'origine nantais) at the apex of ciliated airway epithelial cells. Oxidative degradation of apical HA produces low-molecular-weight HA fragments that signal via RHAMM and RON to increase ciliary beat frequency (CBF). A function-blocking anti-RHAMM antibody reduced the CBF response; co-immunoprecipitation confirmed physical RHAMM–RON association.\",\n      \"method\": \"Co-immunoprecipitation, immunohistochemistry, function-blocking antibodies, tyrosine kinase inhibitor (genistein), RON inhibitor (β-MSP), HA synthesis inhibition\",\n      \"journal\": \"American journal of respiratory cell and molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP confirming physical interaction, functional antibody blocking, pharmacological inhibitors; single lab\",\n      \"pmids\": [\"17395888\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RHAMM, not CD44, mediates HA-induced vascular smooth muscle cell migration through a PI3K-dependent Rac activation pathway. siRNA knockdown of RHAMM inhibited both HA-induced migration and Rac activation; siRNA knockdown of CD44 inhibited RhoA activation without affecting migration. PI3K inhibitor LY294002 blocked HA-induced Rac activation and migration downstream of RHAMM.\",\n      \"method\": \"siRNA knockdown of RHAMM and CD44, Rho GTPase pull-down activity assays, PI3K inhibitor, Rho kinase inhibitor, blocking anti-CD44 antibody, migration assays\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA epistasis with pull-down assays for Rac/RhoA activity, pharmacological dissection; single lab\",\n      \"pmids\": [\"16934786\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Intracellular RHAMM associates with BRCA1 and BARD1; this association attenuates the mitotic-spindle-promoting activity of RHAMM. Extracellular RHAMM–CD44 partnering sustains CD44 surface display and enhances CD44-mediated ERK1/2 signaling.\",\n      \"method\": \"Co-immunoprecipitation (RHAMM–BRCA1, RHAMM–BARD1, RHAMM–CD44), cell surface display assays, ERK1/2 signaling assays (as described in cited primary studies reviewed here)\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — review paper summarizing co-IP data from primary studies; mechanistic claims are based on previously published work, not new experiments in this paper\",\n      \"pmids\": [\"18354082\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Intracellular RHAMM(Δ163) regulates interphase and mitotic spindle microtubule stability through ERK1,2 activity. RHAMM−/− MEFs show strongly acetylated interphase microtubules, multipolar spindles, and aberrant cytokinesis, rescued by RHAMM or mutant active MEK1. RHAMM(Δ163) binds α- and β-tubulin via a C-terminal leucine zipper and directly binds ERK1 via a D-site motif (confirmed by co-IP and pulldown). RHAMM(Δ163)–ERK1/2–MEK1–tubulin complexes identified; RHAMM mutants defective in ERK1 binding fail to rescue microtubule defects.\",\n      \"method\": \"RHAMM−/− MEFs, mutant active MEK1 rescue, co-immunoprecipitation/pulldown of RHAMM–ERK1/2–MEK1–tubulin, in vitro tubulin polymerization assay, D-site mutant analysis, in vitro kinase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — genetic KO rescue, in vitro binding assays, mutagenesis of ERK1-binding D-site, in vitro kinase assays; multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"20558733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BRCA1 and RHAMM, together with AURKA and TPX2, cooperate in essential microtubule reorganization during MCF10A apicobasal polarization. BRCA1 facilitates this reorganization, while AURKA impairs it; RHAMM and TPX2 form a negative feedback loop regulating AURKA. Mechanistically, elevated RHAMM and TPX2 oppose AURKA activity at the mitotic cell cortex during polarization.\",\n      \"method\": \"MCF10A 3D polarization assay, siRNA knockdown of BRCA1/RHAMM/AURKA/TPX2, immunofluorescence, genetic association analysis in BRCA1 mutation carriers\",\n      \"journal\": \"PLoS biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — 3D cell polarization functional assay with siRNA epistasis and imaging; single lab, but multiple orthogonal methods\",\n      \"pmids\": [\"22110403\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RHAMM expression is transcriptionally controlled by YAP/TEAD: YAP binds RHAMM promoter at specific sites and drives RHAMM transcription. Mevalonate pathway activity regulates YAP phosphorylation and nuclear-cytoplasmic localization, thereby controlling RHAMM transcription. Simvastatin inhibits breast cancer cell migration/invasion by reducing YAP-activated RHAMM transcription via geranylgeranylation, Rho GTPase activation, and actin cytoskeleton rearrangement, largely independently of MST/LATS kinase activity.\",\n      \"method\": \"Reporter assays (RHAMM promoter luciferase), ChIP for YAP/TEAD binding, siRNA knockdown of YAP, simvastatin treatment, geranylgeraniol rescue, YAP phosphorylation and localization analysis, in vitro/in vivo migration/invasion assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP demonstrating direct YAP/TEAD-promoter binding, reporter assays, siRNA epistasis, pharmacological rescue, in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"24367099\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RHAMM is required for Aurora kinase A activation and correct TPX2 localization during mitotic spindle assembly. Silencing RHAMM delays spindle assembly kinetics, mislocalizes TPX2, and attenuates localized Aurora kinase A activation, reducing mitotic spindle length. The RHAMM–TPX2 complex requires a C-terminal basic leucine zipper in RHAMM and a domain including the nuclear localization signal in TPX2.\",\n      \"method\": \"siRNA silencing, live-cell imaging of spindle assembly kinetics, immunofluorescence of Aurora kinase A activity (pAURKA), co-immunoprecipitation of RHAMM–TPX2, deletion mutant analysis\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — co-IP with domain mapping, live-cell kinetics, phospho-AURKA immunofluorescence, siRNA phenotype; multiple orthogonal methods in one study\",\n      \"pmids\": [\"24875404\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"RHAMM acts as a co-activator of E2F1 to transcriptionally up-regulate fibronectin. E2F1 directly up-regulates RHAMM, which in turn enhances E2F1-mediated fibronectin expression and integrin-β1–FAK signaling, promoting cytoskeletal remodeling and tumor cell transmigration across endothelial layers. RHAMM depletion abolishes fibronectin expression and endothelial transmigration in E2F1-activated cells.\",\n      \"method\": \"Co-immunoprecipitation (E2F1–RHAMM), ChIP for E2F1 binding to RHAMM promoter, siRNA knockdown, fibronectin promoter reporter assay, transmigration assays, xenograft in vivo model\",\n      \"journal\": \"The Journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, ChIP, reporter assay, functional transmigration assay; single lab\",\n      \"pmids\": [\"25042645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"In zebrafish heart regeneration, HA and Hmmr are required for epicardial epithelial-to-mesenchymal transition (EMT) and epicardial cell migration into the regenerating ventricle. Chemical inhibition of FAK or Src kinases (downstream effectors of Hmmr) prevented epicardial cell migration, implicating a HA/Hmmr/FAK/Src pathway in cardiac regeneration.\",\n      \"method\": \"Zebrafish morpholino knockdown of Hmmr, HA synthesis inhibitor, chemical inhibition of FAK and Src, ventricular resection model, proteomics identification of Hmmr\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockdown with FAK/Src pharmacological epistasis in zebrafish; single lab, ortholog study\",\n      \"pmids\": [\"26156497\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RHAMM regulates planar germ cell division in the testis by associating with the mitotic spindle; loss of RHAMM from the spindle causes defective planar divisions of undifferentiated germ cells, leading to premature niche exit, germ cell depletion, hypofertility, and seminoma. RHAMM expression in testis is regulated by the testis-specific polyadenylation protein CFIm25, which is downregulated in human seminomas.\",\n      \"method\": \"Mouse models (Rhamm knockout, CFIm25 models), immunofluorescence of spindle-associated RHAMM, analysis of human seminoma specimens, CFIm25 expression studies\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO mouse model with defined spindle orientation phenotype, human seminoma validation; single lab\",\n      \"pmids\": [\"27543603\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"HMMR acts at centrosomes in a PLK1-dependent pathway that localizes active Ran and modulates cortical NuMA–dynein complex positioning to correct mispositioned mitotic spindles. Hmmr-knockout mice exhibit neonatal lethality with defective neural development and spindle orientation defects. HMMR overexpression induces phenotypes consistent with increased active Ran including spindle orientation defects.\",\n      \"method\": \"Hmmr-knockout mouse generation and phenotyping, immunofluorescence (active Ran, NuMA, dynein at cortex), PLK1 pathway epistasis, spindle orientation quantification in neural progenitors\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with in vivo developmental phenotype, mechanistic pathway placement via Ran/NuMA/dynein localization, PLK1 epistasis, overexpression phenotype; multiple orthogonal methods\",\n      \"pmids\": [\"28994651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"HMMR acts as a nonmotor adaptor that dampens Eg5-mediated forces during mitosis by localizing TPX2 and promoting formation of inhibitory TPX2–Eg5 complexes. Genomic deletion or siRNA silencing of HMMR disturbs spindle microtubule organization, bipolar kinetochore attachments, and increases aneuploidy. A conserved HMMR motif with homology to kinesin Kif15 is required for interkinetochore tension and anaphase entry. HMMR defects are alleviated by chemical inhibition of Eg5 but not Kif15 silencing.\",\n      \"method\": \"siRNA silencing, HMMR genomic deletion, live-cell imaging, immunofluorescence (kinetochore tension, spindle architecture), chemical inhibition of Eg5 and Kif15 silencing, aneuploidy quantification, rescue with conserved motif constructs\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic deletion and siRNA with mechanistic rescue, multiple spindle/kinetochore functional readouts, Eg5 inhibitor epistasis; multiple orthogonal methods in one study\",\n      \"pmids\": [\"29386294\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Phosphorylation of BACH1 during mitosis is required for its interaction with HMMR and CRM1 to stabilize mitotic spindle orientation. Mitosis-specific phosphorylations of BACH1 were identified by SILAC mass spectrometry; mutation of these phosphorylation sites abolished both spindle orientation rescue and HMMR interaction in BACH1-depleted cells. BACH1 loses chromatin/gene expression partners during mitosis but retains interaction with HMMR.\",\n      \"method\": \"SILAC mass spectrometry, co-immunoprecipitation (BACH1–HMMR), phosphomutant expression rescue, spindle orientation imaging, BACH1 knockdown and re-expression\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — SILAC MS identification of phosphorylation, co-IP, phosphomutant rescue; single lab\",\n      \"pmids\": [\"29459360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"RHAMM expression is transcriptionally downregulated by p53. Reporter assays showed p53-dependent repression is mediated at the RHAMM promoter (including first exon and first intron). RHAMM protein levels peak in S phase and decrease before the G2/M mRNA peak, indicating post-transcriptional control in addition to transcriptional regulation during the cell cycle.\",\n      \"method\": \"Reporter assays (RHAMM promoter luciferase), p53-inducible transgenic cell system, nutlin-3/doxorubicin/paclitaxel treatment, RT-PCR and Western blot across cell cycle fractions\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter assays, p53-inducible system, multiple p53-activating agents; single lab\",\n      \"pmids\": [\"18971636\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"In rat brain, RHAMM exists as multiple molecular weight forms (66, 75, 85–90 kDa) with differential subcellular distribution. The 75 kDa form is enriched in mitochondrial fractions and associates with mitochondrial membranes (retained in osmotically shocked mitochondria, liberated by alkali carbonate). Brain RHAMM binds calmodulin in a Ca2+-dependent manner via calmodulin-affinity chromatography.\",\n      \"method\": \"Subcellular fractionation, Western blotting, osmotic shock/alkali carbonate extraction of mitochondria, calmodulin-affinity chromatography, HA-Sepharose chromatography, double immunohistochemistry with cytochrome oxidase\",\n      \"journal\": \"Journal of neuroscience research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — subcellular fractionation with biochemical extraction controls, calmodulin affinity chromatography, immunohistochemical co-localization; single lab\",\n      \"pmids\": [\"11433424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"HMMR overexpression in mouse mammary epithelium increases Brca1-mutant tumorigenesis by activating AURKA, reducing ARPC2 localization at the mitotic cell cortex, promoting micronucleation, and activating cGAS-STING and non-canonical NF-κB signaling. Initial tumorigenic events include genomic instability, epithelial-to-mesenchymal transition, and tissue infiltration of tumor-associated macrophages.\",\n      \"method\": \"Transgenic mouse mammary epithelium overexpression of HMMR crossed with Brca1 mutant, immunofluorescence (AURKA, ARPC2 cortical localization), micronucleus assay, cGAS-STING pathway activation assays, NF-κB reporter/assays, macrophage infiltration histology\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo transgenic mouse model with mechanistic pathway readouts; single lab, multiple downstream phenotypic measurements\",\n      \"pmids\": [\"35393420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RHAMM interacts with ANKRD26 as identified by yeast two-hybrid and co-immunoprecipitation. Selective down-regulation of Hmmr in 3T3-L1 cells increased adipogenesis, indicating RHAMM suppresses this differentiation process.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, siRNA knockdown, adipogenesis assay (Oil Red O)\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single co-IP confirmation of yeast two-hybrid interaction; adipogenesis phenotype from single siRNA experiment; single lab\",\n      \"pmids\": [\"22666460\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RHAMM forms an intracellular complex with β-catenin that protects β-catenin from degradation and supports its nuclear translocation, resulting in c-Myc activation and enhanced fibrosarcoma cell proliferation. LMWHA increases HT1080 cell growth in a RHAMM-dependent manner through this β-catenin/c-Myc axis.\",\n      \"method\": \"Co-immunoprecipitation (RHAMM–β-catenin), immunofluorescence, siRNA knockdown, transfection experiments with c-Myc reporter, cell proliferation assays\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP of RHAMM–β-catenin complex, siRNA epistasis, reporter assays; single lab\",\n      \"pmids\": [\"26825774\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"RHAMM-dependent RHAMM/CD44 complexation is upregulated specifically by immobilized (end-on) HA but not by soluble HA in breast cancer cells. CD44/RHAMM co-localization and complexation were demonstrated by FRET microscopy and co-immunoprecipitation; this interaction is regulated in a cell-specific feedback loop via HA presentation format.\",\n      \"method\": \"FRET microscopy, co-immunoprecipitation, immunocytochemistry, comparison of soluble vs. immobilized HA substrates\",\n      \"journal\": \"Acta biomaterialia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — FRET and co-IP are complementary orthogonal methods; single lab, findings on HA presentation dependency\",\n      \"pmids\": [\"33091625\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HMMR promotes prostate cancer progression through a positive feedback loop: HMMR interacts with AURKA and stabilizes AURKA protein by inhibiting its ubiquitination-mediated degradation, which activates mTORC2/AKT signaling; activated AKT promotes E2F1-driven transcription of HMMR, forming a reinforcing loop. mTOR inhibitor partially antagonized HMMR-mediated tumor growth in vivo.\",\n      \"method\": \"Co-immunoprecipitation (HMMR–AURKA), ubiquitination assay, mTORC2/AKT phosphorylation analysis, E2F1 ChIP on HMMR promoter, gain/loss-of-function in vitro/in vivo, mTOR inhibitor treatment\",\n      \"journal\": \"Cell death discovery\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, ubiquitination assay, ChIP, in vivo rescue; single lab\",\n      \"pmids\": [\"36750558\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HMMR forms a complex with FAK and SRC in the cytoplasm to activate NF-κB signaling, independently of membrane CD44 interaction, thereby sustaining CD47 ('don't eat me') signaling and enabling liver cancer immune evasion. HMMR knockout inhibited liver cancer growth and enhanced phagocytosis by macrophages; targeting HMMR enhanced anti-PD-1 treatment by recruiting CD8+ T cells.\",\n      \"method\": \"HMMR−/− liver cancer mouse model, co-immunoprecipitation (HMMR–FAK–SRC), NF-κB reporter assay, CD47 expression analysis, phagocytosis assays, anti-PD-1 combination in vivo\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO, co-IP of cytoplasmic complex, NF-κB pathway readout, phagocytosis functional assay; single lab\",\n      \"pmids\": [\"38838151\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In HCC progression driven by ER stress, HMMR is transcriptionally induced by the ER stress transcription factor CHOP and is ubiquitinated and degraded by the E3 ligase TRIM29. Dynamic TRIM29 expression during HCC progression regulates dynamic HMMR protein expression. HMMR alleviates ER stress by promoting autophagic lysosome activity.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay (TRIM29–HMMR), luciferase reporter assay (CHOP binding to HMMR promoter), ChIP, immunofluorescence (HMMR–autophagy markers), HBV-transgenic mouse model\",\n      \"journal\": \"Cancer communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP, ubiquitination assay, ChIP/luciferase for transcriptional regulation, in vivo mouse model; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"37405956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"RHAMMB isoform (lacking the 15 aa encoded by alternative exon present in RHAMMA) but not RHAMMA promotes pancreatic tumor metastasis in vivo. RHAMMB upregulation in liver metastases correlates with higher EGFR expression, and EGFR knockdown abolished RHAMMB-driven metastasis, placing RHAMMB upstream of EGFR-dependent signaling.\",\n      \"method\": \"RNA-Seq isoform analysis of primary PNET and liver metastases, experimental metastasis mouse models, EGFR knockdown (siRNA), in vivo spontaneous metastasis assays\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — isoform-specific in vivo metastasis models, EGFR epistasis via siRNA; single lab\",\n      \"pmids\": [\"31072393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"RHAMM cytoplasmic localization is required for maintenance of murine embryonic stem cell pluripotency via modulation of ERK1/2 and Aurora kinase A activity at microtubules. RHAMM was not detectable on the ESC cell surface. Hemizygous genomic deletion of Hmmr augmented differentiation and attenuated pluripotency; inhibition of ERK1/2 or Aurora kinase A rescued pluripotency in RHAMM+/− ESCs.\",\n      \"method\": \"Hemizygous Hmmr genomic deletion, immunofluorescence localization in ESCs, small-molecule kinase inhibitor screen, differentiation/pluripotency marker analysis\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic hemizygous deletion with functional pluripotency phenotype, kinase inhibitor epistasis, localization studies; single lab\",\n      \"pmids\": [\"24019927\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"HMMR/RHAMM is a multifunctional, multispatial protein that (1) binds hyaluronan extracellularly via a defined B(X7)B motif and signals through a RHAMM–CD44–ERK1/2 complex to promote cell motility and wound repair, acting downstream of Ras and TGF-β; (2) localizes intracellularly to microtubules, centrosomes, and mitotic spindles, where it stabilizes spindle integrity by cross-linking microtubules via dynein co-association, localizing TPX2 and active Aurora kinase A, dampening Eg5-mediated forces via TPX2–Eg5 complexes, and acting in a PLK1-dependent pathway to orient spindle position through regulation of active Ran and cortical NuMA–dynein; and (3) functions as a signaling adaptor that recruits ERK1/2–MEK1 complexes to microtubule substrates, complexes with β-catenin to sustain Wnt/c-Myc signaling, interacts with FAK/SRC to activate NF-κB, stabilizes AURKA by inhibiting its ubiquitination, and is transcriptionally controlled by YAP/TEAD, p53, CHOP, and FOXM1 while being subject to ubiquitin-mediated proteasomal degradation by TRIM29.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"HMMR/RHAMM is a multifunctional, multispatial protein that couples hyaluronan (HA) signaling at the cell surface to ERK1/2-driven motility and acts intracellularly as a microtubule- and spindle-associated regulator of mitosis [#0, #10, #9]. Extracellularly, RHAMM binds HA through C-terminal B(X7)B motifs that are necessary and sufficient for HA binding, and the same C-terminal region binds heparin [#0, #1]. On ras-transformed and invasive cells, RHAMM (rather than CD44) is the primary mediator of HA-stimulated locomotion, acting downstream of Ras and TGF-\\u03b21 to drive focal adhesion kinase phosphorylation and focal adhesion turnover [#3, #4, #5, #2]. Cell-surface RHAMM is required to localize CD44 to the surface and to assemble CD44\\u2013ERK1/2 complexes that sustain ERK activity, wound resurfacing, and invasion, with RHAMM acting upstream of MEK\\u2013ERK [#10, #11]. RHAMM functions as a signaling adaptor: cytoplasmic RHAMMv4 co-immunoprecipitates with MEK1 and ERK to control ERK activation, and HA signaling through RHAMM activates PI3K-dependent Rac to drive migration [#7, #13]. Intracellularly, RHAMM is a microtubule- and actin-associated protein that targets centrosomes and mitotic spindles, co-associating with dynein intermediate chain to stabilize spindle poles [#9, #8]. It organizes the spindle by cross-linking microtubules in an ERK1/2-dependent manner, localizing TPX2 and active Aurora kinase A, dampening Eg5-mediated forces through inhibitory TPX2\\u2013Eg5 complexes, and acting in a PLK1-dependent pathway that localizes active Ran and positions cortical NuMA\\u2013dynein to orient spindles [#15, #18, #23, #22]. Hmmr knockout causes neonatal lethality with neural spindle-orientation defects and disrupts planar germ cell divisions in the testis, while cytoplasmic RHAMM maintains embryonic stem cell pluripotency via ERK1/2 and Aurora kinase A [#22, #21, #35]. RHAMM expression is transcriptionally controlled by YAP/TEAD, E2F1, CHOP, and p53, and RHAMM protein is degraded by the E3 ligase TRIM29 [#17, #19, #25, #33]. Through stabilization of AURKA against ubiquitination, complexation with \\u03b2-catenin to sustain Wnt/c-Myc signaling, and cytoplasmic FAK/SRC-mediated NF-\\u03baB activation, RHAMM promotes tumorigenesis, metastasis, and immune evasion [#31, #29, #32, #27].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Established the molecular basis of HA recognition by RHAMM, defining a transferable B(X7)B binding motif and placing RHAMM downstream of TGF-\\u03b21 and Ras as the primary HA-motility receptor.\",\n      \"evidence\": \"Site-directed mutagenesis and chimeric rescue of recombinant RHAMM in HA-Sepharose assays; antibody neutralization of HA- and TGF-\\u03b21-induced locomotion\",\n      \"pmids\": [\"7508860\", \"7534313\", \"7693717\", \"7688314\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structure of the HA-bound B(X7)B region not resolved\", \"Relative contribution of heparin binding to physiological signaling unclear\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Connected HA/RHAMM engagement to a rapid, transient tyrosine-kinase signaling output controlling focal adhesion dynamics, identifying FAK as a key effector of HA-stimulated motility.\",\n      \"evidence\": \"Anti-phosphotyrosine immunoblot, vinculin immunofluorescence, antibody microinjection, and tyrosine kinase inhibitors in ras-transformed fibroblasts\",\n      \"pmids\": [\"7518470\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct kinase responsible for FAK phosphorylation not defined\", \"Link between surface RHAMM and intracellular kinase activation not mechanistically resolved at this stage\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstrated RHAMM is an oncogenic node acting downstream of ras whose perturbation reverses transformation and metastasis, elevating RHAMM from a motility receptor to a transformation effector.\",\n      \"evidence\": \"Overexpression, dominant-negative suppressor, and antisense in fibroblasts with in vivo metastasis assays and FAK phosphorylation readouts\",\n      \"pmids\": [\"7541721\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular step by which RHAMM acts downstream of ras not fully defined\", \"Contribution of surface vs intracellular pools to transformation not separated\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Showed soluble RHAMM controls mitotic entry by destabilizing cdc2 mRNA, linking RHAMM to cell cycle regulation beyond motility.\",\n      \"evidence\": \"Soluble RHAMM, dominant-negative and antisense perturbation with Cdc2/Cyclin B1 Western blots and mRNA stability assays\",\n      \"pmids\": [\"8666924\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism connecting RHAMM to mRNA degradation unknown\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identified an intracellular RHAMM isoform (RHAMMv4) functioning as a MEK\\u2013ERK adaptor, establishing RHAMM as a cytoplasmic signaling scaffold distinct from its surface role.\",\n      \"evidence\": \"Confocal/flow localization, co-IP with MEK1 and ERK, dominant-negative and constitutive-activation experiments with ERK kinase assays\",\n      \"pmids\": [\"9556628\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding interface to MEK/ERK not mapped at residue level\", \"Whether scaffolding is constitutive or regulated unclear\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Defined RHAMM as a microtubule- and actin-associated protein, mapping cytoskeletal-binding subdomains and a Ca2+/calmodulin-binding site, revealing a structural role at the cytoskeleton.\",\n      \"evidence\": \"GFP-fusion deletion mutants, microtubule and actin co-sedimentation, calmodulin-affinity chromatography\",\n      \"pmids\": [\"10547355\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional consequence of calmodulin binding not established\", \"Regulation of microtubule binding during cell cycle not addressed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Localized RHAMM to centrosomes and spindle poles via a dynein-interaction domain, establishing its requirement for spindle pole stability and mitotic progression.\",\n      \"evidence\": \"Immunofluorescence, reciprocal co-IP of dynein IC, deletion mutant domain mapping in Xenopus and HeLa extracts\",\n      \"pmids\": [\"12808028\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs dynein-bridged interaction with microtubules not distinguished\", \"Regulation of centrosomal targeting unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Genetic knockout placed cell-surface Rhamm upstream of CD44\\u2013ERK1/2 complex assembly required for wound repair, providing in vivo confirmation of the motogenic axis.\",\n      \"evidence\": \"Rhamm\\u2212/\\u2212 mice, scratch wound and collagen invasion assays, CD44\\u2013ERK co-IP, and rescue by bead-linked Rhamm or active MEK1\",\n      \"pmids\": [\"17158951\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How surface Rhamm controls CD44 trafficking not defined\", \"Stoichiometry of the CD44\\u2013Rhamm\\u2013ERK complex unknown\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Distinguished RHAMM and CD44 signaling outputs in vascular smooth muscle, showing RHAMM drives PI3K\\u2013Rac-dependent migration while CD44 controls RhoA.\",\n      \"evidence\": \"siRNA knockdown, Rho GTPase pull-down assays, PI3K and Rho-kinase inhibitors, migration assays\",\n      \"pmids\": [\"16934786\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular link from RHAMM to PI3K not identified\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Extended the CD44\\u2013RHAMM\\u2013ERK complex to invasive breast cancer dependent on endogenous HA synthesis, and identified a RHAMM\\u2013RON tyrosine kinase axis controlling ciliary beat frequency.\",\n      \"evidence\": \"Co-IP, co-localization, antibody and MEK inhibitor epistasis, HA synthase siRNA; RHAMM\\u2013RON co-IP and function-blocking antibodies in airway epithelium\",\n      \"pmids\": [\"17392272\", \"17395888\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants of complex formation only in invasive cells unknown\", \"RHAMM\\u2013RON interaction interface not mapped\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Linked RHAMM to BRCA1/BARD1 and to p53-dependent transcriptional repression, integrating RHAMM into tumor-suppressor and cell-cycle control networks.\",\n      \"evidence\": \"Co-IP (RHAMM\\u2013BRCA1/BARD1) summarized in review; RHAMM promoter reporter assays in p53-inducible systems with cell-cycle fractionation\",\n      \"pmids\": [\"18354082\", \"18971636\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"BRCA1/BARD1 association reported in a review, not original co-IP here\", \"How BRCA1 attenuates spindle activity mechanistically unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Defined a RHAMM\\u2013ERK1/2\\u2013MEK1\\u2013tubulin complex through a C-terminal leucine zipper and an ERK D-site, establishing that RHAMM controls microtubule stability via localized ERK activity.\",\n      \"evidence\": \"Rhamm\\u2212/\\u2212 MEFs with active-MEK1 rescue, co-IP/pulldown, in vitro tubulin polymerization, D-site mutant analysis and kinase assays\",\n      \"pmids\": [\"20558733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Spatial regulation of ERK activity at the spindle not fully resolved\", \"How tubulin and ERK binding are coordinated unknown\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Placed RHAMM in a TPX2-coupled negative feedback loop opposing AURKA during epithelial polarization, integrating it with BRCA1-dependent microtubule reorganization.\",\n      \"evidence\": \"MCF10A 3D polarization with siRNA of BRCA1/RHAMM/AURKA/TPX2 and imaging\",\n      \"pmids\": [\"22110403\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical basis of the RHAMM\\u2013TPX2\\u2013AURKA feedback not resolved here\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established RHAMM as a spindle-assembly factor required for correct TPX2 localization and localized Aurora kinase A activation, mapping the RHAMM\\u2013TPX2 interaction domains.\",\n      \"evidence\": \"siRNA silencing, live-cell spindle kinetics, pAURKA immunofluorescence, RHAMM\\u2013TPX2 co-IP with deletion mapping\",\n      \"pmids\": [\"24875404\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether RHAMM directly stimulates AURKA or acts via TPX2 not resolved\", \"Regulation of complex assembly during mitosis unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified a feed-forward E2F1\\u2013RHAMM transcriptional loop driving fibronectin expression and integrin-\\u03b21\\u2013FAK signaling for tumor cell transendothelial migration.\",\n      \"evidence\": \"E2F1\\u2013RHAMM co-IP, ChIP on RHAMM promoter, fibronectin reporter, transmigration and xenograft assays\",\n      \"pmids\": [\"25042645\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect co-activation of E2F1 by RHAMM not separated\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Connected RHAMM expression to YAP/TEAD and mevalonate-pathway signaling, identifying a transcriptional input from Hippo/statin-sensitive pathways relevant to cancer cell invasion.\",\n      \"evidence\": \"RHAMM promoter reporter, YAP/TEAD ChIP, YAP siRNA, simvastatin and geranylgeraniol rescue, in vivo invasion assays\",\n      \"pmids\": [\"24367099\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"MST/LATS-independent YAP control mechanism not fully defined\", \"How statin-sensitive geranylgeranylation feeds into YAP not resolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed cytoplasmic RHAMM sustains embryonic stem cell pluripotency through ERK1/2 and Aurora kinase A activity, extending its intracellular role to stem cell self-renewal.\",\n      \"evidence\": \"Hemizygous Hmmr deletion in ESCs, localization, kinase-inhibitor rescue, pluripotency marker analysis\",\n      \"pmids\": [\"24019927\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct targets of RHAMM-regulated kinases in pluripotency not identified\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated a conserved HA/Hmmr/FAK/Src requirement for epicardial EMT and migration in zebrafish heart regeneration, generalizing RHAMM motility signaling to tissue repair.\",\n      \"evidence\": \"Morpholino Hmmr knockdown, HA synthesis inhibition, FAK/Src inhibitors in a ventricular resection model\",\n      \"pmids\": [\"26156497\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct Hmmr\\u2013FAK/Src interaction not shown here\", \"Ortholog study; mammalian relevance not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established RHAMM-dependent spindle association as essential for planar germ cell divisions, with loss causing germ cell depletion and seminoma, and tied RHAMM expression to CFIm25 polyadenylation control.\",\n      \"evidence\": \"Rhamm and CFIm25 mouse models, spindle immunofluorescence, human seminoma analysis\",\n      \"pmids\": [\"27543603\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking RHAMM to division-plane orientation in germ cells not fully resolved\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified a RHAMM\\u2013\\u03b2-catenin complex that stabilizes \\u03b2-catenin and activates c-Myc, linking HA/RHAMM to Wnt-pathway-driven proliferation.\",\n      \"evidence\": \"RHAMM\\u2013\\u03b2-catenin co-IP, immunofluorescence, siRNA, c-Myc reporter and proliferation assays\",\n      \"pmids\": [\"26825774\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How RHAMM protects \\u03b2-catenin from degradation not defined\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined HMMR's role in spindle positioning via a PLK1-dependent pathway localizing active Ran and cortical NuMA\\u2013dynein, with knockout causing neonatal lethality and neural defects.\",\n      \"evidence\": \"Hmmr-knockout mouse phenotyping, Ran/NuMA/dynein localization, PLK1 epistasis, overexpression phenotypes\",\n      \"pmids\": [\"28994651\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular link from HMMR to PLK1 and Ran not fully mapped\", \"How cortical and pole functions are coordinated unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established HMMR as a nonmotor adaptor dampening Eg5 forces through inhibitory TPX2\\u2013Eg5 complexes via a Kif15-homologous motif required for kinetochore tension and anaphase entry.\",\n      \"evidence\": \"siRNA and genomic deletion, live imaging, kinetochore-tension immunofluorescence, Eg5 inhibitor and Kif15 silencing epistasis, motif rescue\",\n      \"pmids\": [\"29386294\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding of HMMR to Eg5 vs TPX2-mediated bridging not fully separated\", \"Structural basis of the Kif15-homology motif not resolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified mitosis-specific BACH1 phosphorylation as required for its HMMR/CRM1 interaction stabilizing spindle orientation, adding a regulated partner to HMMR's spindle function.\",\n      \"evidence\": \"SILAC mass spectrometry, BACH1\\u2013HMMR co-IP, phosphomutant rescue, spindle orientation imaging\",\n      \"pmids\": [\"29459360\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct interface of HMMR\\u2013BACH1 not mapped\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed isoform-specific oncogenic function, with RHAMMB but not RHAMMA driving pancreatic metastasis through EGFR-dependent signaling.\",\n      \"evidence\": \"RNA-Seq isoform analysis, experimental metastasis models, EGFR knockdown epistasis\",\n      \"pmids\": [\"31072393\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of isoform-specific EGFR coupling unknown\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Refined the RHAMM/CD44 interaction as dependent on HA presentation format, with immobilized but not soluble HA upregulating complexation.\",\n      \"evidence\": \"FRET microscopy and co-IP comparing soluble vs immobilized HA in breast cancer cells\",\n      \"pmids\": [\"33091625\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism sensing HA presentation geometry unknown\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placed HMMR in an ER-stress circuit, transcriptionally induced by CHOP and degraded by TRIM29, with HMMR promoting autophagic lysosome activity to relieve ER stress in HCC.\",\n      \"evidence\": \"Co-IP, TRIM29\\u2013HMMR ubiquitination assay, CHOP ChIP/reporter, autophagy marker imaging, HBV-transgenic mouse model\",\n      \"pmids\": [\"37405956\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How HMMR promotes autophagic lysosome activity mechanistically unclear\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated HMMR overexpression cooperates with Brca1 mutation to drive tumorigenesis by activating AURKA, mislocalizing ARPC2, and triggering micronucleation with cGAS-STING and non-canonical NF-\\u03baB signaling.\",\n      \"evidence\": \"Transgenic HMMR-overexpressing mouse mammary epithelium crossed with Brca1 mutant, micronucleus and pathway-activation assays, macrophage histology\",\n      \"pmids\": [\"35393420\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal order of cortical ARPC2 loss and micronucleation not fully resolved\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined positive feedback loops in which HMMR stabilizes AURKA against ubiquitination to drive mTORC2/AKT/E2F1 signaling in prostate cancer, and forms cytoplasmic FAK\\u2013SRC complexes activating NF-\\u03baB to sustain CD47-mediated immune evasion in liver cancer.\",\n      \"evidence\": \"HMMR\\u2013AURKA and HMMR\\u2013FAK\\u2013SRC co-IP, ubiquitination assays, ChIP, NF-\\u03baB reporters, phagocytosis and anti-PD-1 in vivo models\",\n      \"pmids\": [\"36750558\", \"38838151\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether HMMR directly blocks an AURKA E3 ligase not defined\", \"Single-lab studies for each axis\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the same protein partitions between its extracellular HA-receptor pool and its intracellular spindle/adaptor pools, and what governs this switch, remains unresolved.\",\n      \"evidence\": \"No timeline study directly resolves the trafficking and regulatory logic that distributes HMMR across surface, cytoplasmic, microtubule, centrosomal, and mitochondrial pools\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model of full-length HMMR or its bound complexes\", \"Mechanism partitioning HMMR between surface and intracellular pools unknown\", \"Direct vs scaffold-bridged nature of many reported interactions undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [7, 15, 9, 18, 23]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [8, 9, 15]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [18, 23, 31]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [19, 29]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [10, 7, 11, 30]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [7, 15, 29, 32]},\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [8, 9, 15]},\n      {\"term_id\": \"GO:0005815\", \"supporting_discovery_ids\": [9, 22]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 6]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [26]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [9, 18, 22, 23]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 10, 11, 13, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 27, 31, 32, 34]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [17, 19, 25, 33]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [32, 27]}\n    ],\n    \"complexes\": [\n      \"CD44\\u2013RHAMM\\u2013ERK1/2 complex\",\n      \"RHAMM\\u2013ERK1/2\\u2013MEK1\\u2013tubulin complex\",\n      \"RHAMM\\u2013TPX2 (and TPX2\\u2013Eg5) spindle complex\",\n      \"HMMR\\u2013FAK\\u2013SRC cytoplasmic complex\"\n    ],\n    \"partners\": [\n      \"CD44\",\n      \"ERK1/2\",\n      \"MEK1\",\n      \"TPX2\",\n      \"AURKA\",\n      \"DYNC1I (dynein intermediate chain)\",\n      \"BACH1\",\n      \"CTNNB1\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":10,"faith_total":10,"faith_pct":100.0}}